ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Celecoxib: Drug information

Celecoxib: Drug information
(For additional information see "Celecoxib: Patient drug information" and see "Celecoxib: Pediatric drug information")

For abbreviations, symbols, and age group definitions used in Lexicomp (show table)
ALERT: US Boxed Warning
Serious cardiovascular risk:

Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction (MI), and stroke, which can be fatal. This risk may occur early in the treatment and may increase with duration of use.

Celecoxib is contraindicated in the setting of coronary artery bypass graft (CABG) surgery.

Serious gastrointestinal risk:

NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events, including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at higher risk for serious GI events.

Brand Names: US
  • CeleBREX;
  • Elyxyb
Brand Names: Canada
  • ACT Celecoxib [DSC];
  • AG-Celecoxib;
  • APO-Celecoxib;
  • Auro-Celecoxib;
  • BIO-Celecoxib;
  • CeleBREX;
  • JAMP-Celecoxib;
  • M-Celecoxib;
  • Mar-Celecoxib;
  • MINT-Celecoxib;
  • NRA-Celecoxib;
  • PMS-Celecoxib;
  • PMSC-Celecoxib;
  • Priva-Celecoxib [DSC];
  • RIVA-Celecox;
  • SDZ Celecoxib [DSC];
  • TARO-Celecoxib
Pharmacologic Category
  • Analgesic, Nonopioid;
  • Nonsteroidal Anti-inflammatory Drug (NSAID), COX-2 Selective
Dosing: Adult

Dosage guidance:

Safety: Avoid or use with caution in patients at risk for or with existing cardiovascular disease, GI disease, kidney impairment, chronic liver disease, or a bleeding diathesis due to greater risk for adverse events. Consider administering in combination with a proton pump inhibitor in patients at risk for GI bleeding (eg, taking dual antiplatelet therapy or an anticoagulant, ≥60 years of age, high celecoxib doses) (Ref).

Dosing: Use the lowest effective dose for the shortest duration of time.

Acute pain

Acute pain (monotherapy or as an adjunctive agent): Oral: Initial: 400 mg, followed by 200 mg approximately 12 hours later, if needed, on day 1; thereafter, 200 mg twice daily as needed or scheduled; maximum daily maintenance dose: 400 mg/day (Ref). In select patients (eg, advanced age, comorbidity), some experts may initiate at 100 mg twice daily (Ref).

Anti-inflammatory

Anti-inflammatory (eg, for arthritis associated with inflammatory rheumatic disease): Oral: Initial: 200 mg once daily or 100 mg twice daily; may increase to a maximum of 200 mg twice daily for several weeks during a disease flare until the flare resolves.

Dysmenorrhea

Dysmenorrhea: Oral: Initial: 400 mg, followed by an additional 200 mg approximately 12 hours later, if needed, on day 1; maintenance dose: 200 mg twice daily as needed; maximum daily maintenance dose: 400 mg/day. Begin at menses onset or 1 to 2 days prior to onset of menses for severe symptoms; usual duration: 1 to 5 days (Ref).

Gout, treatment, acute flares

Gout, treatment, acute flares (off-label use):

Oral: Initial: 400 mg, followed by 200 mg approximately 12 hours later on day 1, then continue 200 mg twice daily thereafter; maximum daily maintenance dose: 400 mg/day (Ref). Initiate within 24 to 48 hours of flare onset; reduce dose as symptoms improve. Discontinue a few days after resolution of clinical signs (usual total duration: 5 to 7 days); longer duration may be required if therapy is delayed (Ref).

Migraine, acute treatment

Migraine, acute treatment:

Note: Limit use to ≤14 days per month to avoid medication-overuse headache (Ref). For use as monotherapy in mild to moderate attacks not associated with vomiting or severe nausea (Ref). Administration early in the course of a migraine attack, at the first sign of pain, may improve response to treatment (Ref).

Oral: 120 mg as a single dose. Maximum: 120 mg per 24 hours (Ref).

Osteoarthritis

Osteoarthritis: Oral: 200 mg once daily or 100 mg twice daily.

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.

Altered kidney function:

CrCl ≥60 mL/minute: No dosage adjustment necessary (<1% of the drug excreted in the urine) (Ref).

CrCl >30 to <60 mL/minute: No dosage adjustment necessary (<1% of the drug excreted in the urine) (Ref). However, use the lowest effective dose for the shortest duration possible. Use of analgesics other than nonsteroidal anti-inflammatory drugs (NSAIDs) or topical NSAIDs may be preferred. Avoid use in patients at high risk for acute kidney injury (ie, volume depleted, hypotensive, elderly, or taking concurrent nephrotoxic medications) (Ref).

CrCl ≤30 mL/minute: Avoid use due to increased risk of acute kidney injury (Ref); Use of analgesics other than NSAIDs or topical NSAIDs are preferred. However, in select patients where alternatives are not effective, after careful assessment of risks versus benefits, use of celecoxib may be considered; use the lowest effective dose for the shortest duration possible with close monitoring of kidney function (Ref).

Hemodialysis, intermittent (thrice weekly): Unlikely to be significantly dialyzable (high protein binding, large Vd): Avoid use, as patients with end-stage kidney disease may be at increased risk for bleeding (eg, GI), cardiovascular adverse effects, and loss of residual kidney function (Ref). However, in select patients after careful assessment of risks versus benefits, use of celecoxib may be considered; use the lowest effective dose for the shortest duration possible (Ref).

Peritoneal dialysis: Unlikely to be significantly dialyzable (high protein binding, large Vd): Avoid use, as patients with end-stage kidney disease may be at increased risk for bleeding (eg, GI), cardiovascular adverse effects, and loss of residual kidney function (Ref). However, in select patients after careful assessment of risks versus benefits, use of celecoxib may be considered; use the lowest effective dose for the shortest duration possible (Ref).

CRRT: Avoid use (Ref).

PIRRT (eg, sustained, low-efficiency diafiltration): Avoid use (Ref).

Acute kidney injury while on celecoxib therapy: Discontinue use (Ref).

Dosing: Hepatic Impairment: Adult

Mild impairment (Child-Pugh class A): No dosage adjustment necessary; AUC increased ~40% in mild hepatic impairment compared with healthy subjects.

Moderate impairment (Child-Pugh class B): Reduce dose by 50%.

Severe impairment (Child-Pugh class C): Use is not recommended.

Abnormal liver function tests (persistent or worsening): Discontinue use.

Dosing: Older Adult

Initiate at the lowest recommended dose. The AUC in older adults (>65 years of age, especially females and patients weighing <50 kg) may be increased by 50% compared with younger subjects.

Dosing: Pediatric

(For additional information see "Celecoxib: Pediatric drug information")

Juvenile idiopathic arthritis

Juvenile idiopathic arthritis (JIA): Note: Use the lowest effective dose for the shortest duration of time, consistent with individual patient goals.

Children ≥2 years and Adolescents:

≥10 kg to ≤25 kg: Oral: 50 mg twice daily.

>25 kg: Oral: 100 mg twice daily.

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Pediatric

Children ≥2 years and Adolescents: Oral:

Baseline:

Mild or moderate impairment: There are no dosage adjustments provided in the manufacturer's labeling; however, since <1% of the drug is excreted in the urine, dosage adjustment is not necessary (Ref). Based on unpublished data, AUC was ~40% lower in adult patients with chronic renal insufficiency (GFR 35 to 60 mL/minute) compared with subjects with normal renal function due to a higher apparent clearance.

Severe impairment: Use is not recommended.

Advanced renal disease: Use is not recommended; however, if celecoxib treatment cannot be avoided, monitor renal function closely.

During therapy: Abnormal renal function tests (persistent or worsening): Discontinue use.

Dosing: Hepatic Impairment: Pediatric

Children ≥2 years and Adolescents: Oral:

Moderate hepatic impatient: Reduce dose by 50%; monitor closely.

Severe hepatic impairment: Use is not recommended; has not been studied.

Adverse Reactions (Significant): Considerations
Cardiovascular events

Use of nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with an increased risk of serious adverse cardiovascular (CV) events, including acute myocardial infarction (MI), cerebrovascular accident, and CV death. New-onset hypertension or exacerbation of hypertension may occur with NSAID use which may also contribute to an increased risk of CV events (Ref). New-onset or exacerbation of heart failure may also occur with cyclooxygenase (COX)-2 selective NSAIDs (ie, coxibs), including celecoxib, and nonselective NSAIDs (eg, naproxen) resulting in an increased risk of hospitalizations for heart failure and death in patients with heart failure (Ref).

Data collected by the Coxib and traditional NSAID Trialists’ (CNT) Collaborative has shown that use of COX-2 selective NSAIDs, including celecoxib, may increase the risk of major vascular events as compared to nonselective NSAIDs (Ref); however, data from the PRECISION trial showed no difference with regards to risk between celecoxib, naproxen, or ibuprofen after a treatment duration of therapy of ~3 years (Ref). Additional trials and registry data are also conflicted with regards to the comparative risk of CV events among the COX-2 selective and nonselective NSAIDs (Ref). However, data in those with established heart disease consistently reveals an increased risk of harm with NSAID use (Ref). The FDA states that there is insufficient data to determine if risk of MI or stroke is definitely higher or lower for any particular NSAID as compared to another (Ref).

Mechanism: Dose- and time-related; inhibition of COX-2 by NSAIDs results in a reduction in the production of prostaglandin I2 (prostacyclin) in the vascular endothelium (Ref); animal studies have shown that reduced prostacyclin activity may result in a predisposition to vascular injury (Ref). In addition, prostaglandins inhibit sodium resorption in the thick ascending loop of Henle and collecting tubule; therefore, a reduction in prostaglandin synthesis by NSAIDs may cause sodium and fluid retention and result in hypertension and decreased efficacy of diuretics (Ref).

Onset: Varied; increased risk may be apparent within the first weeks following initiation of treatment (Ref); longer duration of therapy may further increase risk (Ref).

Risk factors:

• ≥65 years of age

• Higher doses (especially with regards to CV thrombotic risk) (Ref)

• Longer duration of use and frequent use (eg, ≥22 days per month) (Ref)

• Preexisting cardiovascular disease (CVD) or presence of risk factors for CVD, including use following coronary artery bypass graft surgery (Ref)

- Note: Relative risk appears to be similar in those with and without known CVD or risk factors for CVD; however, absolute incidence of serious CV thrombotic events appears to be higher in patients with known CVD or risk factors for CVD due to an increased baseline risk (Ref)

Gastrointestinal events

Use of nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with an increased risk of serious gastrointestinal (GI) adverse events, including gastrointestinal inflammation, gastrointestinal hemorrhage, gastrointestinal ulcer, and gastrointestinal perforation; severity may range from asymptomatic to fatal (Ref). Selective cyclooxygenase (COX)-2 NSAIDs, including celecoxib, appear to be associated with a lower risk of significant GI adverse events as compared to nonselective NSAIDs (Ref); the concomitant use of low-dose aspirin therapy may diminish the safety advantage of COX-2 selective NSAIDs over nonselective NSAIDs (Ref).

Mechanism: Dose- and time-related; inhibition of COX-1 by NSAIDs results in a reduction in the production of mucosal-protective prostaglandin E2). COX-2 selective NSAIDs may block COX-1 in the GI tract, albeit to a lesser degree as compared to nonselective NSAIDs, and therefore have the ability to cause damage (Ref).

Onset: Varied; GI events can occur at any time during use and without warning symptoms.

Risk factors:

• ≥65 years of age (Ref)

• Longer duration of use

• Higher doses (eg, celecoxib 400 mg twice daily (Ref))

• Prior history of peptic ulcer disease and/or GI bleeding

• Concomitant use of agents known to increase the risk of GI bleeding (eg, aspirin (Ref); anticoagulants, corticosteroids (Ref); selective serotonin reuptake inhibitors (Ref))

• Comorbid Helicobacter pylori infection (Ref)

• Advanced liver disease/cirrhosis

• Coagulopathy

• Smoking

• Consumption of alcohol

• People with poor general health status

• Small intestine damage: Small intestine bacterial overgrowth (SIBO), including SIBO induced by proton pump inhibitor therapy, may be associated with an increased risk of small intestine damage (Ref)

Hematologic effects

Use of celecoxib may result in anemia (Ref). Although no cases of drug-induced hemolytic anemia associated with celecoxib use have been reported, this adverse event has been reported with other nonsteroidal anti-inflammatory drugs (NSAIDs), including both non-selective and cyclooxygenase (COX)-2 selective agents (Ref). While nonselective NSAIDs (eg, ibuprofen) may cause prolonged bleeding time and an increased risk for hemorrhage, COX-2 selective NSAIDS (eg, celecoxib), are less likely to result in abnormal platelet function or prolonged bleeding time (Ref).

Mechanism:

Anemia: Not clearly established; anemia may be due to occult or gross blood loss, or in some cases, drug-induced antibodies leading to autoimmune hemolysis.

Prolonged bleeding time: Inhibition of COX-1 causes a decrease in the production of prostaglandins, prostacyclins, and thromboxanes, including thromboxane A2 (TxA2) (Ref). Therefore, patients exposed to NSAIDs, especially nonselective NSAIDs (eg, naproxen), may exhibit a decrease in platelet adhesion and aggregation and subsequent prolonged bleeding time (Ref).

Onset: Prolonged bleeding time: Rapid; suppression of platelet COX-1 activity occurs within hours of administration (Ref). In patients receiving antithrombotic therapy after myocardial infarction, the use of NSAIDs, including COX-2 selective NSAIDs (eg, celecoxib), has been associated with an increased risk of bleeding and excess thrombotic events even after short-term treatment (eg, <3 days) (Ref).

Risk factors:

• Bleeding events:

- Preexisting coagulation disorders

- Concomitant use of agents known to increase the risk of bleeding (eg, anticoagulants (Ref); antithrombotics (Ref); antiplatelet agents [eg, aspirin, clopidogrel (Ref)]; selective serotonin reuptake inhibitors (Ref); or serotonin norepinephrine reuptake inhibitors)

Hepatic effects

Use of nonsteroidal anti-inflammatory drugs (NSAIDs), including celecoxib, may result in mild and transient transaminase elevations. The incidence of hepatic adverse events appears similar between celecoxib, naproxen, and ibuprofen (Ref); diclofenac exhibits a higher rate of hepatotoxic events as compared to other NSAIDs (Ref). Rarely, use of celecoxib has resulted in acute hepatitis and drug-induced liver injury (DILI) with a hepatocellular, cholestatic, or mixed pattern of liver injury; celecoxib-induced liver injury requiring liver transplantation has been described (Ref). The pattern of celecoxib-induced liver injury may resemble sulfonamide-induced livery injury (ie, short latency and abrupt onset) and cross-reactivity has been described (Ref).

Mechanism: Not clearly established; some cases may exhibit immunoallergic features similar to sulfonamide-induced liver injury (Ref).

Onset: DILI: Varied; cases with immunoallergic features may occur after a short duration of treatment (median: 12 days; range: 1 to 42), whereas cases without immunoallergic features may occur following prolonged use (6 months to 2 years) (Ref).

Risk factors:

• Prior sulfonamide-induced liver injury (Ref)

Hypersensitivity reactions (immediate and delayed)

Immediate (eg, anaphylaxis, urticaria/angioedema) (Ref) and delayed hypersensitivity reactions have been reported with celecoxib. Delayed hypersensitivity reactions include mild reactions such as maculopapular rash and fixed drug eruption (Ref); severe cutaneous adverse reactions (SCARs) including acute generalized exanthematous pustulosis (Ref), Stevens-Johnson syndrome/toxic epidermal necrolysis (Ref) and drug rash with eosinophilia and systemic symptoms (Ref) have been documented. Vasculitis of the skin has also been reported (Ref).

Mechanism: Non–dose-related; immunologic. Immediate hypersensitivity reactions (eg, anaphylaxis, urticaria) are typically IgE-mediated (Ref). Delayed hypersensitivity reactions, including maculopapular eruptions, fixed drug eruption, and SCARs, are thought to be T-cell-mediated (Ref).

Onset:

Immediate hypersensitivity reactions: Rapid; occur within 1 hour of administration but may occur several hours after exposure (Ref).

Delayed hypersensitivity reactions:

Maculopapular reactions: Intermediate; typically occur 7 to 14 days after initiation (Ref).

Other reactions (including SCARs): Varied; occur 1 to 8 weeks after initiation (Ref). Vasculitis of the skin has been reported 3 to 4 days after initiating therapy (Ref).

Risk factors:

• Selective cyclooxygenase (COX)-2 inhibitors (eg, celecoxib) are generally tolerated in patients with NSAID-exacerbated respiratory disease (NERD) (Ref), patients with histories of isolated respiratory reaction to NSAIDs (Ref), and in many patients with cutaneous reactions to NSAIDs (Ref); however, cross-reactions may occur, especially in patients with histories of urticaria/angioedema (Ref).

• There is limited published information regarding possible cross-reactivity between celecoxib and other sulfonamides (Ref). Cross-reactivity between celecoxib, a nonantibiotic sulfonamide, and antibiotic sulfonamides is unlikely to occur (Ref).

• Cross-reactivity among COX-2 inhibitors is not known, although there are reports of patients who have tolerated celecoxib following a reaction to etoricoxib (Ref). Cross-reactivity with nabumetone has been reported (Ref).

Kidney effects

Use of nonsteroidal anti-inflammatory drugs (NSAIDs), including celecoxib, is associated with an increased risk of several kidney-specific effects: Hemodynamically-mediated acute kidney injury (AKI), interstitial nephritis (with or without nephrotic syndrome), and renal papillary necrosis.

Hemodynamically-mediated AKI: Hemodynamically-mediated AKI may occur following use of either cyclooxygenase (COX)-2 selective NSAIDs, including celecoxib, or nonselective NSAIDs (eg, naproxen) (Ref); the risk may be greater with nonselective NSAIDs, especially indomethacin (Ref). The risk of developing AKI is decreased upon discontinuation (Ref). In patients who develop AKI, kidney function is likely to return to baseline following prompt discontinuation of the offending NSAID and supportive care (Ref); however, the mechanism of the damage and other concurrent factors can contribute to irreversibility.

Acute interstitial nephritis (AIN) with or without nephrotic syndrome: Patients may develop NSAID-associated proteinuria combined with interstitial nephritis and varying degrees of kidney impairment; the “classic triad” of fever, rash, and eosinophilia is less commonly observed in NSAID-associated AIN than with antibiotic-induced AIN (Ref). In patients with concurrent nephrotic syndrome, kidney histology may reveal minimal change glomerulonephritis or membranous nephropathy (Ref). While use of celecoxib has been associated with this clinical picture (Ref), the risk may be greatest with fenoprofen as compared to other NSAIDS (Ref). Proteinuria generally improves within weeks following discontinuation; full recovery may require treatment and take up to a year (Ref).

Papillary necrosis: Chronic use of NSAIDs, including celecoxib, has resulted in the development of papillary necrosis which may occur in conjunction with chronic interstitial nephritis and progressive decline in glomerular filtration rate as a clinical syndrome known as analgesic nephropathy (Ref). However, controversy exists on the degree to which NSAID use increases the risk for chronic kidney disease and analgesic nephropathy (Ref). Acute papillary necrosis may occur following NSAID overdose, especially in a setting of severe dehydration or intravascular volume depletion (Ref).

Mechanism:

Hemodynamically-mediated AKI: Dose- and time-related; inhibition of COX-1 and COX-2 by NSAIDs results in a reduced production of nephroprotective prostaglandins and subsequent attenuation of renal vasodilation (Ref). In addition, an increase in vasoconstriction of the afferent arteriole and impaired renal blood flow causes a reduction in the glomerular capillary pressure and filtration (Ref).

AIN with or without nephrotic syndrome: Not clearly established. Following inhibition of COX-1 and COX-2 by NSAIDs, arachidonic acid is formed which may be further metabolized to leukotrienes via the lipoxygenase pathway; leukotrienes may increase vascular permeability within glomerular capillaries and peritubular capillaries and increase lymphocyte recruitment and activation (Ref).

Papillary necrosis: Time-related; exact mechanism is not clearly established; may be due to direct toxicity and/or inhibition of prostaglandin-mediated vasodilation resulting in ischemic necrosis (Ref).

Onset:

AKI: Rapid; may occur within days of treatment initiation (Ref).

AIN with or without nephrotic syndrome: Varied; mean time of onset of ~5 months (range: 2 weeks to 18 months) has been described following use of nonselective NSAIDs (Ref).

Risk factors:

• AKI:

- Preexisting kidney impairment

- Chronic kidney disease (Ref). Note: Higher cumulative doses (eg, celecoxib >100 mg/day) may increase the risk for progression of chronic kidney disease (Ref)

- ≥65 years of age (Ref). Note: NSAID-associated AKI may also occur in pediatric patients, even at therapeutic doses (Ref)

• Hemodynamically-mediated AKI:

- Preexisting conditions which result in decreased effective arterial circulation (ie, conditions where renal blood flow/renal perfusion may be dependent on prostaglandin-mediated vasodilation) (Ref)

Volume depletion (eg, due to concomitant diuretic use, nausea, or vomiting)

Heart failure (Ref)

Cirrhosis and ascites (Ref)

Nephrotic syndrome

- Concomitant use of diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or calcineurin inhibitors (Ref)

• AIN with or without nephrotic syndrome: Prior history of NSAID-induced nephrotic syndrome; recurrence has been described with a nonselective NSAID (Ref)

• Papillary necrosis (acute):

- Massive NSAID ingestion (Ref)

- Dehydration (Ref)

- Intravascular volume depletion (Ref)

• Papillary necrosis (chronic)/analgesic nephropathy: Chronic concomitant use of other analgesics (eg, aspirin, acetaminophen) (Ref)

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.

1% to 10%:

Cardiovascular: Acute myocardial infarction (<2%), angina pectoris (<2%), chest pain (<2%), coronary artery disease (<2%), edema (<2%), exacerbation of hypertension (<2%), palpitations (<2%), peripheral edema (2%), tachycardia (<2%)

Dermatologic: Alopecia (<2%), cellulitis (<2%), contact dermatitis (<2%), dermatitis (<2%), diaphoresis (<2%), ecchymoses (<2%), erythematous rash (<2%), maculopapular rash (<2%), pruritus (<2%), skin changes (<2%), skin photosensitivity (<2%), urticaria (<2%), xeroderma (<2%)

Endocrine & metabolic: Albuminuria (<2%), hot flash (<2%), hypercholesterolemia (<2%), hyperglycemia (<2%), hypokalemia (<2%), increased nonprotein nitrogen (<2%), weight gain (<2%)

Gastrointestinal: Abdominal pain (4%), anorexia (<2%), constipation (<2%), diarrhea (6%), diverticulitis of the gastrointestinal tract (<2%), dysgeusia (3%), dyspepsia (9%), dysphagia (<2%), eructation (<2%), esophagitis (<2%), flatulence (2%), gastritis (<2%), gastroenteritis (<2%), gastroesophageal reflux disease (<2%), hemorrhoids (<2%), hiatal hernia (<2%), increased appetite (<2%), melena (<2%), stomatitis (<2%), tenesmus (<2%), vomiting (<2%), xerostomia (<2%)

Genitourinary: Cystitis (<2%), dysuria (<2%), hematuria (<2%), urinary frequency (<2%)

Hematologic & oncologic: Anemia (<2%), thrombocythemia (<2%)

Hepatic: Increased liver enzymes (<3 x ULN: ≤6%), increased serum alkaline phosphatase (<2%)

Hypersensitivity: Facial edema (<2%), hypersensitivity reaction (<2%)

Nervous system: Anxiety (<2%), depression (<2%), drowsiness (<2%), fatigue (<2%), hypertonia (<2%), hypoesthesia (<2%), migraine (<2%), nervousness (<2%), pain (<2%), paresthesia (<2%), peripheral pain (<2%), vertigo (<2%)

Neuromuscular & skeletal: Arthralgia (<2%), increased creatine phosphokinase in blood specimen (<2%), lower limb cramp (<2%), myalgia (<2%), synovitis (<2%), tendinopathy (<2%)

Otic: Deafness (<2%), tinnitus (<2%)

Renal: Increased blood urea nitrogen (<2%), increased serum creatinine (<2%), nephrolithiasis (<2%)

Respiratory: Aggravated bronchospasm (<2%), bronchitis (<2%), bronchospasm (<2%), cough (<2%), dyspnea (<2%), epistaxis (<2%), flu-like symptoms (<2%), laryngitis (<2%), pharyngitis (2%), pneumonia (<2%), rhinitis (2%), sinusitis (5%), upper respiratory tract infection (8%)

Miscellaneous: Cyst (<2%), fever (<2%)

<1%:

Cardiovascular: Heart failure, pulmonary embolism, syncope, thrombophlebitis, ventricular fibrillation

Dermatologic: Gangrene of skin and/or subcutaneous tissue

Gastrointestinal: Cholelithiasis, esophageal perforation, gastrointestinal hemorrhage, hemorrhagic colitis, intestinal obstruction, intestinal perforation, pancreatitis

Hematologic & oncologic: Thrombocytopenia

Infection: Sepsis

Nervous system: Ataxia, cerebrovascular accident, suicidal tendencies

Renal: Acute kidney injury

Frequency not defined:

Cardiovascular: Coronary thrombosis

Dermatologic: Erythema multiforme, exfoliative dermatitis

Gastrointestinal: Alveolar osteitis (post-oral surgery patients), gastrointestinal inflammation, gastrointestinal perforation, gastrointestinal ulcer

Postmarketing:

Cardiovascular: Acute coronary syndrome (Kounis syndrome) (Regis 2015), deep vein thrombosis (Chan 2005), hypertension (Handler 2003), vasculitis (allergic) (Schneider 2002)

Dermatologic: Acute generalized exanthematous pustulosis (Goeschke 2004; Lee 2016), Stevens-Johnson syndrome (La Grenade 2005), toxic epidermal necrolysis (Berger 2002; Friedman 2002; Perna 2003), vasculitis of the skin (Drago 2004)

Endocrine & metabolic: Hypoglycemia, hyponatremia

Gastrointestinal: Ageusia

Hematologic & oncologic: Agranulocytosis, aplastic anemia, leukopenia, pancytopenia

Hepatic: Cholestasis (Chamouard 2005), hepatic failure (El Hajj 2009), hepatic necrosis, hepatitis (including cholestatic hepatitis) (Larrey 2019), jaundice (Chamouard 2005)

Hypersensitivity: Anaphylaxis (Chamberlin 2009), angioedema (Gagnon 2003), drug reaction with eosinophilia and systemic symptoms (Lee 2008), fixed drug eruption (Ammar 2019), nonimmune anaphylaxis

Nervous system: Anosmia, aseptic meningitis (Papaioannides 2004), intracranial hemorrhage

Renal: Interstitial nephritis (Henao 2002), renal papillary necrosis (Akhund 2003)

Contraindications

Hypersensitivity (eg, anaphylaxis, serious skin reactions) to celecoxib, sulfonamides, aspirin, other NSAIDs, or any component of the formulation; patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs; use in the setting of CABG surgery.

Note: Although the FDA-approved product labeling states this medication is contraindicated in patients with hypersensitivity to sulfonamide-containing drugs, the scientific basis of this cross-sensitivity has been challenged. See “Warnings/Precautions” for more detail.

Canadian labeling: Additional contraindications (not in US labeling): Pregnancy (third trimester); women who are breast-feeding; severe, uncontrolled heart failure; active gastrointestinal ulcer (gastric, duodenal, peptic); active gastrointestinal bleeding; inflammatory bowel disease; cerebrovascular bleeding; severe liver impairment or active hepatic disease; severe renal impairment (CrCl <30 mL/minute) or deteriorating renal disease; known hyperkalemia; use in patients <18 years of age

Warnings/Precautions

Concerns related to adverse effects:

• Medication-overuse headache: Acute migraine agents used more frequently than recommended (eg, >14 days per month) may lead to worsening of headaches (medication-overuse headache). Symptoms include migraine-like daily headaches or a marked increase in frequency of migraine attacks. Withdrawal treatment may be necessary in the setting of overuse (AHS [Ailani 2021]; manufacturer’s labeling).

• Sulfonamide ("sulfa") allergy: The FDA-approved product labeling for many medications containing a sulfonamide chemical group includes a broad contraindication in patients with a prior allergic reaction to sulfonamides. There is a potential for cross-reactivity between members of a specific class (eg, two antibiotic sulfonamides). However, concerns for cross-reactivity have previously extended to all compounds containing the sulfonamide structure (SO2NH2). An expanded understanding of allergic mechanisms indicates cross-reactivity between antibiotic sulfonamides and nonantibiotic sulfonamides may not occur or at the very least this potential is extremely low (Brackett 2004; Johnson 2005; Slatore 2004; Tornero 2004). In particular, mechanisms of cross-reaction due to antibody production (anaphylaxis) are unlikely to occur with nonantibiotic sulfonamides. T-cell-mediated (type IV) reactions (eg, maculopapular rash) are not well understood and it is not possible to completely exclude this potential based on current insights. In cases where prior reactions were severe (SJS/TEN), some clinicians choose to avoid exposure to these classes.

Disease-related concerns:

• Asthma: The manufacturer's labeling states to not administer to patients with aspirin-sensitive asthma due to severe and potentially fatal bronchospasm that has been reported in such patients having received aspirin and the potential for cross reactivity with other NSAIDs. The manufacturer also states to use with caution in patients with other forms of asthma. However, in patients with known aspirin-exacerbated respiratory disease (AERD), the use of celecoxib initiated at a low dose with gradual titration in patients with stable, mild to moderate persistent asthma has been used without incident (Morales 2013).

• Bariatric surgery: Gastric ulceration: Avoid chronic use of oral nonselective NSAIDs after bariatric surgery; development of anastomotic ulcerations/perforations may occur (Bhangu 2014; Mechanick 2020). Short-term use of celecoxib or IV ketorolac are recommended as part of a multimodal pain management strategy for postoperative pain (Chou 2016; Horsley 2019; Thorell 2016).

• Cytochrome P450 isoenzyme 2C9 deficiency: Use with caution in patients with known or suspected deficiency of cytochrome P450 isoenzyme 2C9 (CYP 2C9*3/*3); poor metabolizers may have higher plasma levels due to reduced metabolism; consider reduced initial doses (initiate therapy with 25% to 50% of the lowest starting dose [eg, 50% to 75% dose reduction]) (CPIC [Theken 2020]). Alternate therapies should be considered in patients with juvenile idiopathic arthritis (JIA) who are poor metabolizers of CYP2C9.

• Hepatic impairment: Use with caution in patients with moderate hepatic impairment; dosage adjustment recommended. Not recommended for patients with severe hepatic impairment.

• Renal impairment: Use with caution in patients with renal impairment.

Special populations:

• Pediatric: Use with caution in pediatric patients with systemic-onset JIA; serious adverse reactions, including disseminated intravascular coagulation, may occur. Long-term cardiovascular risk in children has not been evaluated.

Warnings: Additional Pediatric Considerations

Consider alternate therapy in JIA patients who are identified to be CYP2C9 poor metabolizers. In a small pediatric study (n=4), the AUC of celecoxib was ~10 times higher in a child who was homozygous for CYP2C9*3, compared to children who were homozygous for the *1 allele (n=2) or who had the CYP2C9*1/*2 genotype; further studies are needed to determine if carriers of the CYP2C9*3 allele are at increased risk for cardiovascular toxicity or dose related adverse effects of celecoxib, especially with long-term, high-dose use of the drug (Stempak 2005).

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Capsule, Oral:

CeleBREX: 50 mg, 100 mg, 200 mg, 400 mg

Generic: 50 mg, 100 mg, 200 mg, 400 mg

Solution, Oral:

Elyxyb: 120 mg/4.8 mL (4.8 mL) [contains alcohol, usp, levomenthol, peg-40 hydrog castor oil(cremophor rh40), polyoxyl/peg-35 castor oil(cremophor el)]

Elyxyb: 120 mg/4.8 mL (4.8 mL) [contains alcohol, usp, levomenthol, peg-40 hydrog castor oil(cremophor rh40), polyoxyl/peg-35 castor oil(cremophor el); peppermint flavor]

Generic Equivalent Available: US

May be product dependent

Pricing: US

Capsules (CeleBREX Oral)

50 mg (per each): $5.35

100 mg (per each): $11.44

200 mg (per each): $18.76

400 mg (per each): $28.15

Capsules (Celecoxib Oral)

50 mg (per each): $2.14 - $2.16

100 mg (per each): $0.33 - $4.62

200 mg (per each): $0.36 - $7.58

400 mg (per each): $0.81 - $11.37

Solution (Elyxyb Oral)

120MG/4.8ML (per mL): $36.45

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Capsule, Oral:

CeleBREX: 100 mg [contains fd&c blue #2 (indigotine,indigo carmine)]

CeleBREX: 200 mg

Generic: 100 mg, 200 mg

Administration: Adult

Oral:

May be administered without regard to meals.

Capsules: May be swallowed whole or the entire contents emptied onto a teaspoon of cool or room temperature applesauce and administered immediately with water. The contents of the capsules sprinkled onto applesauce may be stored under refrigeration for up to 6 hours.

Oral solution: Administer full dose directly from bottle. Administer partial dose with a calibrated measuring device (not a household teaspoon or tablespoon).

Administration: Pediatric

Oral: Lower doses may be administered without regard to meals (may administer with food to reduce GI upset); larger doses should be administered with food to improve absorption. Capsules may be swallowed whole or the entire contents emptied onto a teaspoon of cool or room temperature applesauce and ingested immediately with water. The sprinkled contents of the capsule on applesauce may be stored under refrigeration for up to 6 hours.

Medication Guide and/or Vaccine Information Statement (VIS)

An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:

NSAIDs: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020998s050lbl.pdf#page=21

Use: Labeled Indications

Anti-inflammatory: Relief of the signs/symptoms of ankylosing spondylitis or rheumatoid arthritis.

Dysmenorrhea: Treatment of primary dysmenorrhea.

Juvenile idiopathic arthritis: Relief of the signs/symptoms of juvenile idiopathic arthritis (JIA) in patients 2 years and older.

Migraine, acute treatment: Acute treatment of migraine with or without aura in adults.

Osteoarthritis: Relief of the signs/symptoms of osteoarthritis.

Pain, acute: Management of acute pain.

Use: Off-Label: Adult

Gout, treatment, acute flares

Medication Safety Issues
Sound-alike/look-alike issues:

CeleBREX may be confused with CeleXA, Cerebyx, Cervarix, Clarinex

Metabolism/Transport Effects

Substrate of CYP2C9 (major), CYP3A4 (minor); Note: Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; Inhibits CYP2D6 (weak)

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.

5-Aminosalicylic Acid Derivatives: Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of 5-Aminosalicylic Acid Derivatives. Risk C: Monitor therapy

Acemetacin: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Risk X: Avoid combination

Ajmaline: Sulfonamides may enhance the adverse/toxic effect of Ajmaline. Specifically, the risk for cholestasis may be increased. Risk C: Monitor therapy

Alcohol (Ethyl): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of GI bleeding may be increased with this combination. Risk C: Monitor therapy

Aliskiren: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Aliskiren. Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Aliskiren. Risk C: Monitor therapy

Alpelisib: May decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers). Risk C: Monitor therapy

Aminoglycosides: Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants. Risk C: Monitor therapy

Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). Risk X: Avoid combination

Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). Risk C: Monitor therapy

Angiotensin II Receptor Blockers: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Angiotensin II Receptor Blockers. The combination of these two agents may also significantly decrease glomerular filtration and renal function. Risk C: Monitor therapy

Angiotensin-Converting Enzyme Inhibitors: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Angiotensin-Converting Enzyme Inhibitors. Risk C: Monitor therapy

Anticoagulants: Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective) may enhance the anticoagulant effect of Anticoagulants. Risk C: Monitor therapy

Aspirin: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective). Management: Concurrent use of aspirin at doses beyond cardioprotective levels is not recommended. While concurrent use of low-dose aspirin with a COX-2 inhibitor is permissable, patients should be monitored closely for signs/symptoms of GI ulceration/bleeding. Risk D: Consider therapy modification

Bemiparin: Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Bemiparin. Management: Avoid concomitant use of bemiparin and nonsteroidal anti-inflammatory agents (NSAIDs) due to the increased risk of bleeding. If concomitant use is unavoidable, monitor closely for signs and symptoms of bleeding. Risk D: Consider therapy modification

Beta-Blockers: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Beta-Blockers. Risk C: Monitor therapy

Bile Acid Sequestrants: May decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Risk C: Monitor therapy

Bisphosphonate Derivatives: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Bisphosphonate Derivatives. Both an increased risk of gastrointestinal ulceration and an increased risk of nephrotoxicity are of concern. Risk C: Monitor therapy

Corticosteroids (Systemic): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective). Risk C: Monitor therapy

CycloSPORINE (Systemic): Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of CycloSPORINE (Systemic). Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents. Management: Consider alternatives to nonsteroidal anti-inflammatory agents (NSAIDs). Monitor for evidence of nephrotoxicity, as well as increased serum cyclosporine concentrations and systemic effects (eg, hypertension) during concomitant therapy with NSAIDs. Risk D: Consider therapy modification

CYP2C9 Inducers (Moderate): May decrease the serum concentration of Celecoxib. Risk C: Monitor therapy

CYP2C9 Inhibitors (Moderate): May increase the serum concentration of Celecoxib. Risk C: Monitor therapy

Dapsone (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Risk C: Monitor therapy

Deferasirox: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. Risk C: Monitor therapy

Desmopressin: Nonsteroidal Anti-Inflammatory Agents may enhance the hyponatremic effect of Desmopressin. Risk C: Monitor therapy

Digoxin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin. Risk C: Monitor therapy

Drospirenone-Containing Products: May enhance the hyperkalemic effect of Nonsteroidal Anti-Inflammatory Agents. Risk C: Monitor therapy

Eplerenone: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Eplerenone. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Eplerenone. Risk C: Monitor therapy

Estrogen Derivatives: Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective) may enhance the thrombogenic effect of Estrogen Derivatives. Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective) may increase the serum concentration of Estrogen Derivatives. Risk C: Monitor therapy

Heparin: Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Heparin. Management: Decrease the dose of heparin or nonsteroidal anti-inflammatory agents (NSAIDs) if coadministration is required. Risk D: Consider therapy modification

Herbal Products with Anticoagulant/Antiplatelet Effects (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur. Risk C: Monitor therapy

HydrALAZINE: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of HydrALAZINE. Risk C: Monitor therapy

Ketorolac (Nasal): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Risk X: Avoid combination

Ketorolac (Systemic): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Ketorolac (Systemic). Risk X: Avoid combination

Lithium: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Lithium. Management: Consider reducing the lithium dose when initiating a NSAID. Monitor for increased lithium therapeutic/toxic effects if a NSAID is initiated/dose increased, or decreased effects if a NSAID is discontinued/dose decreased. Risk D: Consider therapy modification

Local Anesthetics: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Local Anesthetics. Specifically, the risk for methemoglobinemia may be increased. Risk C: Monitor therapy

Loop Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the diuretic effect of Loop Diuretics. Loop Diuretics may enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Management: Monitor for evidence of kidney injury or decreased therapeutic effects of loop diuretics with concurrent use of an NSAID. Consider avoiding concurrent use in CHF or cirrhosis. Concomitant use of bumetanide with indomethacin is not recommended. Risk D: Consider therapy modification

Lumacaftor and Ivacaftor: May decrease the serum concentration of CYP2C9 Substrates (High Risk with Inhibitors or Inducers). Lumacaftor and Ivacaftor may increase the serum concentration of CYP2C9 Substrates (High Risk with Inhibitors or Inducers). Risk C: Monitor therapy

Macimorelin: Nonsteroidal Anti-Inflammatory Agents may diminish the diagnostic effect of Macimorelin. Risk X: Avoid combination

Mecamylamine: Sulfonamides may enhance the adverse/toxic effect of Mecamylamine. Risk X: Avoid combination

MetFORMIN: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of MetFORMIN. Risk C: Monitor therapy

Methotrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Methotrexate. Management: Avoid coadministration of higher dose methotrexate (such as that used for the treatment of oncologic conditions) and NSAIDs. Use caution if coadministering lower dose methotrexate and NSAIDs. Risk D: Consider therapy modification

Methoxsalen (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Methoxsalen (Systemic). Risk C: Monitor therapy

Mifamurtide: Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Mifamurtide. Risk X: Avoid combination

Naftazone: May enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents. Risk C: Monitor therapy

Nitric Oxide: May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia. Risk C: Monitor therapy

Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of other Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk for gastrointestinal toxicity is increased. Risk X: Avoid combination

Nonsteroidal Anti-Inflammatory Agents (Topical): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of gastrointestinal (GI) toxicity is increased. Management: Coadministration of systemic nonsteroidal anti-inflammatory drugs (NSAIDs) and topical NSAIDs is not recommended. If systemic NSAIDs and topical NSAIDs, ensure the benefits outweigh the risks and monitor for increased NSAID toxicities. Risk D: Consider therapy modification

Omacetaxine: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased. Risk C: Monitor therapy

Phenylbutazone: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Risk X: Avoid combination

Polyethylene Glycol-Electrolyte Solution: Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Polyethylene Glycol-Electrolyte Solution. Risk C: Monitor therapy

Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. Risk C: Monitor therapy

Potassium Salts: Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Potassium Salts. Risk C: Monitor therapy

Potassium-Sparing Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Potassium-Sparing Diuretics. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Potassium-Sparing Diuretics. Risk C: Monitor therapy

PRALAtrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of PRALAtrexate. More specifically, NSAIDS may decrease the renal excretion of pralatrexate. Management: Avoid coadministration of pralatrexate with nonsteroidal anti-inflammatory drugs (NSAIDs). If coadministration cannot be avoided, closely monitor for increased pralatrexate serum levels or toxicity. Risk D: Consider therapy modification

Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia. Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia. Avoid lidocaine/prilocaine in infants receiving such agents. Risk C: Monitor therapy

Probenecid: May increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents. Risk C: Monitor therapy

Prostaglandins (Ophthalmic): Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Prostaglandins (Ophthalmic). Nonsteroidal Anti-Inflammatory Agents may also enhance the therapeutic effects of Prostaglandins (Ophthalmic). Risk C: Monitor therapy

Quinolones: Nonsteroidal Anti-Inflammatory Agents may enhance the neuroexcitatory and/or seizure-potentiating effect of Quinolones. Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Quinolones. Risk C: Monitor therapy

Rifapentine: May decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers). Risk C: Monitor therapy

Selective Serotonin Reuptake Inhibitors: May enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective). Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors. Risk C: Monitor therapy

Sincalide: Drugs that Affect Gallbladder Function may diminish the therapeutic effect of Sincalide. Management: Consider discontinuing drugs that may affect gallbladder motility prior to the use of sincalide to stimulate gallbladder contraction. Risk D: Consider therapy modification

Sodium Nitrite: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Sodium Nitrite. Combinations of these agents may increase the likelihood of significant methemoglobinemia. Risk C: Monitor therapy

Sodium Phosphates: May enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of acute phosphate nephropathy may be enhanced. Risk C: Monitor therapy

Tacrolimus (Systemic): Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Tacrolimus (Systemic). Risk C: Monitor therapy

Tenofovir Products: Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Tenofovir Products. Management: Seek alternatives to these combinations whenever possible. Avoid use of tenofovir with multiple NSAIDs or any NSAID given at a high dose due to a potential risk of acute renal failure. Diclofenac appears to confer the most risk. Risk D: Consider therapy modification

Tenoxicam: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Risk X: Avoid combination

Thiazide and Thiazide-Like Diuretics: May enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Thiazide and Thiazide-Like Diuretics. Risk C: Monitor therapy

Thioridazine: CYP2D6 Inhibitors (Weak) may increase the serum concentration of Thioridazine. Management: Consider avoiding concomitant use of thioridazine and weak CYP2D6 inhibitors. If combined, monitor closely for QTc interval prolongation and arrhythmias. Some weak CYP2D6 inhibitors list use with thioridazine as a contraindication. Risk D: Consider therapy modification

Tolperisone: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Tolperisone. Specifically, the risk of hypersensitivity reactions may be increased. Tolperisone may enhance the therapeutic effect of Nonsteroidal Anti-Inflammatory Agents. Risk C: Monitor therapy

Tricyclic Antidepressants: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of major adverse cardiac events (MACE), hemorrhagic stroke, ischemic stroke, and heart failure may be increased. Tricyclic Antidepressants may enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents. Risk C: Monitor therapy

Triflusal: Nonsteroidal Anti-Inflammatory Agents may decrease the protein binding of Triflusal. Specifically, NSAIDs may decrease protein binding of the active Triflusal metabolite. Triflusal may decrease the protein binding of Nonsteroidal Anti-Inflammatory Agents. Risk C: Monitor therapy

Vancomycin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Vancomycin. Risk C: Monitor therapy

Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. Risk C: Monitor therapy

Food Interactions

Peak concentrations are delayed when taken with a high-fat meal. Management: Administer without regard to meals.

Capsules: AUC is increased by 10% to 20% when taken with a high-fat meal.

Reproductive Considerations

Nonsteroidal anti-inflammatory drugs (NSAIDs) may delay or prevent rupture of ovarian follicles. This may be associated with infertility that is reversible upon discontinuation of the medication. Consider discontinuing use in patients having difficulty conceiving or those undergoing investigation of fertility.

Based on available information, NSAIDs can be continued in patients with rheumatic and musculoskeletal diseases who are planning to father a child (ACR [Sammaritano 2020]).

Pregnancy Considerations

The use of nonsteroidal anti-inflammatory drugs (NSAIDs) close to conception may be associated with an increased risk of miscarriage due to cyclooxygenase-2 inhibition interfering with implantation (Bermas 2014; Bloor 2013).

Birth defects have been observed following in utero NSAID exposure in some studies; however, data are conflicting (Bloor 2013). Nonteratogenic effects, including prenatal constriction of the ductus arteriosus, persistent pulmonary hypertension of the newborn, oligohydramnios, necrotizing enterocolitis, renal dysfunction or failure, and intracranial hemorrhage have been observed in the fetus/neonate following in utero NSAID exposure (Bermas 2014; Bloor 2013). Maternal NSAID use may cause fetal renal dysfunction leading to oligohydramnios. Although rare, this may occur as early as 20 weeks' gestation and is more likely to occur with prolonged maternal use. Oligohydramnios may be reversible following discontinuation of the NSAID (Dathe 2019; FDA 2020). In addition, nonclosure of the ductus arteriosus postnatally may occur and be resistant to medical management (Bermas 2014; Bloor 2013).

Maternal use of NSAIDs should be avoided beginning at 20 weeks' gestation. If NSAID use is necessary between 20 and 30 weeks' gestation, limit use to the lowest effective dose and shortest duration possible; consider ultrasound monitoring of amniotic fluid if treatment extends beyond 48 hours and discontinue the NSAID if oligohydramnios is found (FDA 2020). Because NSAIDs may cause premature closure of the ductus arteriosus, product labeling for celecoxib specifically states use should be avoided starting at 30 weeks' gestation.

Based on available information, NSAIDs can be continued during the first 2 trimesters of pregnancy in patients with rheumatic and musculoskeletal diseases; use in the third trimester is not recommended (ACR [Sammaritano 2020]).

Treatment for migraine headaches in pregnant patients should be individualized (AHS [Ailani 2021]). The acute treatment of migraine headaches during pregnancy should be initiated with an agent other than an NSAID. If an NSAID is needed as second-line therapy, treatment should be limited to the second trimester and total duration of therapy should be no longer than 48 hours. An NSAID other than celecoxib may be preferred (ACOG 2022).

NSAIDs may be used as part of a multimodal approach to pain relief following cesarean delivery (ACOG 2019).

Breastfeeding Considerations

Celecoxib is present in breast milk.

Data related to the presence of celecoxib in breast milk are available from multiple studies.

• Breast milk was sampled at intervals over 48 hours in 6 women, 6.5 to 15 months postpartum, following a single dose of celecoxib 200 mg. Peak breast milk concentrations (0.07 to 0.33 mg/L) occurred between 2 and 4 hours after the dose. Authors of the study calculated the estimated infant dose of celecoxib via breast milk to be 0.011 to 0.21 mg/kg/day providing a relative infant dose (RID) of 0.17% to 0.3% (Gardiner 2006).

• The transfer of celecoxib into breast milk was evaluated in 5 breastfeeding women who ranged from 3 to 22 months postpartum. Breast milk samples were collected over a period of 24 hours from 3 women taking celecoxib 200 mg/day for several weeks. Plasma concentrations were collected 4 hours after the dose in 2 breastfeeding infants. Maximum celecoxib concentrations averaged 0.139 mg/L and were reached in breast milk ~2 to 3 hours after the dose. Celecoxib breast milk concentrations were below the limit of detection (<0.010 mg/L) at 12 and 24 hours; infant plasma concentrations were also below the limit of detection. Two additional women were given a single dose of celecoxib 200 mg and breast milk and venous blood samples were collected over a period of 8 hours. Breast milk and maternal concentrations peaked at 2 to 4 hours. The maximum breast milk concentrations of celecoxib were 0.17 mg/L and 0.269 mg/L. The average concentration of celecoxib in breast milk among all 5 women ranged from 0.038 to 0.083 mg/L (mean 0.66 mg/L) over the course of 8 hours. Using the average breast milk concentration, the authors calculated the estimated infant dose via breast milk to be 0.0098 mg/kg/day providing a relative infant dose (RID) of 0.3% (Hale 2004).

• Breast milk was sampled in one lactating woman 5 months postpartum who took celecoxib 100 mg twice daily for 4 doses following an appendectomy. The highest concentration was 0.133 mg/L, which occurred 4.75 hours following her last dose. Authors of the study calculated the estimated infant dose of celecoxib via breast milk to be 0.02 mg/kg/day. The half-life of celecoxib in breast milk was calculated to be 4 to 6.5 hours (Knoppert 2003).

• In general, breastfeeding is considered acceptable when the RID of a medication is <10% (Anderson 2016; Ito 2000).

Adverse events were not observed in 2 breastfeeding infants 17 and 22 months of age (Hale 2004).

Nonopioid analgesics, including nonsteroidal anti-inflammatory drugs (NSAIDs), are preferred for breastfeeding patients who require pain control peripartum or for surgery outside of the postpartum period (ABM [Martin 2018]; ABM [Reece-Stremtan 2017]) and short-term use of celecoxib is considered acceptable (ABM [Reece-Stremtan 2017]). NSAIDs are considered compatible for the treatment of rheumatic and musculoskeletal diseases in lactating patients; agents with a short half-life and established safety data in infants may be preferred (ACR [Sammaritano 2020]). NSAIDs may be used to treat acute migraine in lactating patients (ACOG 2022).

According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother. Maternal use of NSAIDs should be avoided if the breastfeeding infant has platelet dysfunction, thrombocytopenia, or a ductal-dependent cardiac lesion (ABM [Martin 2018]; ABM [Reece-Stremtan 2017]; Bloor 2013).

Monitoring Parameters

CBC (periodically throughout treatment); hemoglobin/hematocrit (during long-term therapy; anemic patients); basic metabolic panel (periodically throughout treatment); occult blood loss; signs/symptoms of liver disease, including periodic LFTs; renal function (urine output, serum BUN and creatinine); therapeutic response (pain, range of motion, grip strength, mobility, ADL function), inflammation; blood pressure (baseline and during treatment); weight gain, edema; bleeding, bruising; GI effects (abdominal pain, bleeding, dyspepsia); signs of immediate or delayed hypersensitivity reactions.

JIA: Monitor for development of abnormal coagulation tests with systemic onset JIA.

Mechanism of Action

Inhibits prostaglandin synthesis by decreasing the activity of the enzyme, cyclooxygenase-2 (COX-2), which results in decreased formation of prostaglandin precursors; has antipyretic, analgesic, and anti-inflammatory properties. Celecoxib does not inhibit cyclooxygenase-1 (COX-1) at therapeutic concentrations.

Pharmacokinetics (Adult Data Unless Noted)

Absorption:

Capsule: Prolonged due to low solubility.

Oral solution: Rapid (Pal 2017).

Distribution: Vd (apparent):

Capsule: Children and Adolescents ~7 to 16 years (steady-state): 8.3 ± 5.8 L/kg (Stempak 2002); Adults: ~400 L.

Oral solution: Adults: ~288 to 743 L (Pal 2017; manufacturer’s labeling).

Protein binding: ~97% primarily to albumin; binds to alpha1-acid glycoprotein to a lesser extent.

Metabolism: Hepatic via CYP2C9; forms inactive metabolites (a primary alcohol, corresponding carboxylic acid, and its glucuronide conjugate).

Bioavailability:

Capsule: Absolute: Unknown.

Oral solution: 144% (relative to capsule) (Pal 2017).

Half-life elimination:

Capsule: Children and Adolescents ~7 to 16 years (steady-state): 6 ± 2.7 hours (range: 3 to 10 hours) (Stempak 2002); Adults: ~11 hours (fasted).

Oral solution: Adults: 0.7 to 1 hour (Pal 2017; manufacturer’s labeling).

Time to peak:

Capsule: Children: Median: 3 hours (range: 1 to 5.8 hours) (Stempak 2002); Adults: ~3 hours.

Oral solution: Adults: 0.7 to 1 hour (Pal 2017; manufacturer’s labeling).

Excretion: Feces (~57% as metabolites, <3% as unchanged drug); urine (27% as metabolites, <3% as unchanged drug); primary metabolites in feces and urine: Carboxylic acid metabolite (73% of dose); low amounts of glucuronide metabolite appear in urine.

Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)

Altered kidney function: Capsule: AUC is approximately 40% lower in patients with a CrCl of 35 to 60 mL/minute.

Hepatic function impairment: Capsule: AUC is increased approximately 40% in patients with mild impairment (Child-Pugh class A) and 180% in patients with moderate impairment (Child-Pugh class B).

Pediatric: The AUC and Cmax following administration of a capsule contents sprinkled on applesauce were reported to be similar as administration of an intact capsule (Krishnaswami 2012).

Older adult (>65 years of age): Capsule: Cmax is 40% higher and AUC is 50% higher.

Race/ethnicity: Capsule: AUC is approximately 40% higher in Black patients compared with White patients.

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AE) United Arab Emirates: Algoxib | Arthrix | Arthromax | Celdol | Celebrex | Celecon | Celemac | Coxib | Gloxib | Movydia | Nexib | Qualcox | Revcox | Rumabrex;
  • (AR) Argentina: Algitrat x | Algybrex | Celebrex | Celecoxib richet | Celemax | Coxel | Coxtenk | Niflam | Tisorek;
  • (AT) Austria: Celebrex | Celecoxib pfizer | Celecoxib ratiopharm;
  • (AU) Australia: Apo celecoxib | Blooms the chemist celecoxib | Celaxib | Celebrex | Celecoxib actavis | Celecoxib an | Celecoxib APOTEX | Celecoxib gh | Celecoxib rbx | Celecoxib sandoz | Celexi | Chemmart celecoxib | Kudeq | Noumed celecoxib | Terry white chemists celecoxib;
  • (BD) Bangladesh: Acicox | Celecox-r | Celenta | Celox-r | Celoxib | Ciox | Cox B | Coxib | Cyclo-2 | Dicoxib | Ezy | Selecox;
  • (BE) Belgium: Celebrex | Celecoxib ab | Celecoxib APOTEX | Celecoxib eg | Celecoxib sandoz | Celecoxib teva | Onsenal;
  • (BF) Burkina Faso: Celebid | Celebrex;
  • (BG) Bulgaria: Aclexa | Algoxib | Celebrex | Celecoxib ecopharm | Coxi | Definax | Tevacoxib;
  • (BR) Brazil: Celebra | Celecoxibe | Cibex | Coques | Dicoxibe | Ducox | Foxis;
  • (CH) Switzerland: Celebrex | Celecoxib actavis | Celecoxib axapharm | Celecoxib helvepharm | Celecoxib mepha | Celecoxib pfizer | Celecoxib sandoz | Celecoxib spirig hc | Celecoxib xiromed | Celecoxib zentiva;
  • (CI) Côte d'Ivoire: Celebrex | Celecoxib sp | Celox-r | Inibrex;
  • (CL) Chile: Argium | Artrexib | Capsure | Celebra | Celebra fem | Celebra max | Celedox | Celerium | Celevitae | Coques | Coxdos | Coxel | Dolertab | Gesix | Nodocib | Valdyne;
  • (CN) China: Celebrex;
  • (CO) Colombia: Artroxil | Atrixib | Cefinix | Celebrex | Celicob | Cicloxx | Colecoxib | Dilox | Flonar | Lexfin | Miodar | Sosedol;
  • (CR) Costa Rica: Doloxene;
  • (CZ) Czech Republic: Aclexa | Celebrex | Celekoxib Mylan;
  • (DE) Germany: Celebrex | Celecaxiro | Celecox hexal | Celecoxib 1A pharma | Celecoxib abz | Celecoxib acino | Celecoxib actavis | Celecoxib AL | Celecoxib alembic | Celecoxib aurobindo | Celecoxib beta | Celecoxib heumann | Celecoxib micro labs | Celecoxib mylan | Celecoxib pfizer | Celecoxib puren | Celecoxib ratiopharm | Celecoxib stada | Celecoxib TAD | Celecoxib zentiva;
  • (DO) Dominican Republic: Algitrat | Artrox | Bicoxib | Celbib | Celebra | Celebrex | Celeco | Celecofran | Celeconav | Celecoxib mk | Celeflan | Coxal | Impedil | Maximus | Nexera | Revcox;
  • (EC) Ecuador: Algivex | Celebjar | Celebrex | Celecoxib la sante | Celeridan | Celevitae | Dolocox | Fullcox | Gesix | Julcox | Revibra;
  • (EE) Estonia: Aclexa | Celebrex | Celecoxib accord;
  • (EG) Egypt: Arythrex | Celeborg | Celebrex | Celecox | Celoxib | Rhuma max;
  • (ES) Spain: Artilog | Axatal | Celebrex | Celecoxib actavis | Celecoxib almus | Celecoxib Alter | Celecoxib amneal | Celecoxib APOTEX | Celecoxib cinfa | Celecoxib combix | Celecoxib kern pharma | Celecoxib Krka | Celecoxib mabo | Celecoxib macleods | Celecoxib mylan | Celecoxib normon | Celecoxib pensa | Celecoxib qualigen | Celecoxib ranbaxy | Celecoxib ratiopharm | Celecoxib sandoz | Celecoxib stada | Celecoxib tarbis | Celecoxib tecnigen | Celecoxib teva | Celecoxib vir | Celecoxib zentiva | Meticel | Onsenal | Oxibin;
  • (ET) Ethiopia: Celofen | Unicelib;
  • (FI) Finland: Celebra | Celecoxib Krka | Celecoxib orion | Celecoxib pfizer | Celecoxib sandoz | Celecoxib stada | Onsenal;
  • (FR) France: Celebrex | Celecoxib arrow | Celecoxib biogaran | Celecoxib cristers | Celecoxib eg | Celecoxib mylan | Celecoxib pfizer | Celecoxib ranbaxy | Celecoxib sandoz | Celecoxib teva | Celecoxib zentiva | Onsenal;
  • (GB) United Kingdom: Celebrex | Onsenal;
  • (GR) Greece: Aclarex | Celebrex;
  • (HK) Hong Kong: Apo celecoxib | Apt celecoxib | Cecolex | Celcoxx | Celebrex | Celxib | Cobix | Eurobrex | Favocox | Keltrex | Selexib | Stadloric | Unibrex;
  • (HR) Croatia: Aclexa | Celixib;
  • (HU) Hungary: Aclexa | Celebrex;
  • (ID) Indonesia: Celcox | Celebrex | Celenox | Novexib;
  • (IE) Ireland: Celebrex | Celecoxib actavis | Celecoxib Krka | Celecoxib rowex | Onsenal;
  • (IL) Israel: Celcox | Celebra;
  • (IN) India: Alcox | Ce | Celact | Celcib | Celcox | Celebix | Celebrex | Celecap | Celedol | Celeheal | Celemax | Celetop | Celfast | Celib | Celicx | Celira | Celkob | Cib | Cobix | Colcibra | Coxib | Eloxib | Femcox | Icel | J flex | Orthocel | Ranselex | Revibra | Selcoxib | Sionara | Speshel | Zecoxib | Zycel;
  • (IT) Italy: Artilog | Celartrox | Celebrex | Celecoxib Alter | Celecoxib aurobindo | Celecoxib doc generici | Celecoxib eg | Celecoxib Krka | Celecoxib mylan pharma | Celecoxib pensa | Celecoxib pfizer | Celecoxib ranbaxy | Celecoxib sandoz | Celecoxib tecnigen | Celecoxib teva | Celecoxib zentiva | Coxiben | Onsenal | Solexa;
  • (JO) Jordan: Celebrex | Flamex | Pedexa;
  • (KE) Kenya: Celcoxx | Celdol | Celebib | Celebrex | Celenta | Celetor | Celex b | Cox B | Coxinhib | Lexib | Oxiceb | Sionara | Zycel;
  • (KR) Korea, Republic of: Anacox | Ausbrex | Barocox | Bearcoxib | Brexib | C cox | C tlex | C trex | Cebicox | Cebucoxy | Cecob | Cecoc | Cecox | Cecoxia | Cecoxib | Celb | Celbesta | Celbic | Celbicoks | Celbicox | Celbit | Celbrec | Celbric | Celbrox | Celcobics | Celcobrex | Celcox | Celcoxbrex | Cele v | Celeb | Celebex | Celebrec | Celebrex | Celecl | Celeco | Celecob | Celecok | Celecop | Celecox | Celecoxin | Celecoxta | Celecsil | Celecxib | Celegen | Celelox | Celemed | Celemin | Celenogic | Celeon | Celepro | Celerox | Celes | Celetis | Celevis | Celewin | Celex | Celexib | Celexibe | Celexstar | Celextar | Celfen | Celibcox | Celleb | Cellox | Celox | Celsc | Celtib | Celvix | Celxib | Cenex | Cereamine | Cerebex | Cerebrin | Cerec | Cerecob | Cerescox | Cereupa | Cerex | Cerocoq | Cexib | Cexibre | Choa celecoxib | Cielcox | Cloxib | Cox 2 | Coxbito | Coxcare | Coxgreen | Coxib | Coxione | Coxnac | Coxren | Cricox | Cybrex | Delcox | Dongkwang celecoxib | Encox | Famcoxib | Genuone celecoxib | Hancox | Hulex | I celcoc | Ilyangbio celecoxib | J brex | J cox | Kelcoxib | Klicox | Laxib | Legolex | Medi c cox | Medibrex | Ncecox | Nelson celecoxib | Newbrex | Newcelcox | Pharma celecoxib | Picox | Samsung celecoxib | Tds celecoxib | Tucoxib | Unibrex | Varocox | Withucox | Yucox;
  • (KW) Kuwait: Celebrex | Coxicel | Selexib;
  • (LB) Lebanon: Celebib | Celebrex | Celecoxib arrow | Coxel | Normocoxib | Revcox;
  • (LT) Lithuania: Aclexa | Celebrex | Celecoxib accord | Celecoxib aurobindo | Celecoxib ranbaxy | Celecoxib zentiva;
  • (LU) Luxembourg: Celebrex | Celecoxib eg | Onsenal;
  • (LV) Latvia: Aclexa | Celebrex | Celecoxib accord | Celecoxib zentiva;
  • (MA) Morocco: Celebrex | Celephi | Isox | Voxcib;
  • (MX) Mexico: Bienuex | Celebrex | Cinaron | Cortax | Delecon | Dropofex | Gruxno | Igef | Tiagorol | Xeletec;
  • (MY) Malaysia: Celebib | Celebrex | Geloxib | Hovid celecoxib | Rabirox | Revcox | Torcoxib | Zobrex;
  • (NG) Nigeria: Celecoxib sandoz | Celecoxx | Celeflox | Celopro | Flacoxto | Markoxib | Recoxib | Rhumacox | Xenobrex;
  • (NL) Netherlands: Celebrex | Celecoxib actavis | Celecoxib CF | Celecoxib mylan | Celecoxib sandoz;
  • (NO) Norway: Celebra | Celebrex | Celecoxib medical valley;
  • (NZ) New Zealand: Celebrex | Celecoxib pfizer | Celostea;
  • (PE) Peru: Articox | Artrixib | Artromycin forte | Augesico | Blockten | C brex | Caditar | Celebrex | Celecoxine | Celecoxmek | Celemexin | Celepoxx | Celestal | Celestalip | Celevit | Celexia | Colcibra | Coques | Coxacib | Coxalgen | Coxicel | Coxiflam | Coxiluxx | Debrox | Diphacoxib | Dolibrex | Dorit | Larcox | Quilxib | Revibra | Sifacox | Thritex | Zipral;
  • (PH) Philippines: Alcoxib | Argicox | Aubrex | Brecxib | Brexen | C flam | Capxibb | Celbex | Celcoxx | Celebrex | Celecorvic | Celecure | Celeflam | Celehan | Celence | Celerich | Celetor | Celevue | Celexib | Celix 200 | Celudex | Cofidec | Cox-2 | Coxapill | Coxbitor | Coxibet | Coxid | Coxidia | Coxiv | Coxoral | Coxsilv | Coxto | Coxtu | Coxzan | Dancoxib | Dialexib | Diaxib | Dolcelox | Ecox | Emicox | Euroflam | Execoxib | Flacoxto | Flamacox | Flamar | Geocoxib | Geoxcib | Goxib | Icox | Kairoxib | Lecoxigan | Lexib | Lincox | Nacoxib | Neocoxib | Occib | Paintab | Penxib | Pharex Celecoxib | Philicoxib | Provicoxib | Recosan | Reduflam | Rheuoxib | Saphlecox | Selecap | Swelcid | Trucox | Vicoxiv | Xelic;
  • (PK) Pakistan: Aflamoxib | Aimcoxib | Articoxib | Artiflex | Bixo | Calaxib | Celadon | Celart | Celbexx | Celebrex | Celecap | Celecomed | Celeeard | Celenor | Celetab | Celox | Celoxib | Celstar | Cewim | Cicxib | Cilavef | Coaxid | Cobix | Coixn | Conxib | Coxban | Coxicap | Cril | Cxib | Dancox | Dorsiflex | Geocoxib | Inicox | Invicox | Ixib | Kalixx | Koib | Koxibnel | Lecob | Lecox | Lezoxib | Max xib | Mifcoxib | Moveryl | Nuzib | Orthocel | Recoxib | Remicox | Rheuoxib | Rival | Sefecox | Seloxx | Xecoc | Xibocel | Xybie | Zeloxt;
  • (PL) Poland: Aclexa | Celebrex | Elecoxel | Onsenal | Zelsiglat;
  • (PR) Puerto Rico: Celebrex | Elyxyb;
  • (PT) Portugal: Celebrex | Celecoxib Alter | Celecoxib bluepharma | Celecoxib Ciclum | Celecoxib cinfa | Celecoxib Fantex | Celecoxib Farmoz | Celecoxib Generis | Celecoxib Krka | Celecoxib Labesfal | Celecoxib mylan | Celecoxib Pentafarma | Celecoxib ratiopharm | Celecoxib sandoz | Celecoxib Tolife | Celecoxib zentiva | Solexa;
  • (PY) Paraguay: Celecoxib dallas | Eliflam | Eliflam forte | Gesix | Percalan;
  • (QA) Qatar: Celcoxx | Celdol | Celebrex | Celetor | Coxicel | Flamex | Qualcox | Revcox | Selexib | Zyoxib;
  • (RO) Romania: Aclexa | Algoxib | Calidem | Celebrex | Celecoxib actavis | Celecoxib terapia | Celetor;
  • (RU) Russian Federation: Celebrex | Celecoxib vial | Dilaxa | Rowcoxib | Simcoxib;
  • (SA) Saudi Arabia: Cebo | Celebrex | Celect | Celoxib | Flamex | Oxibin | Pms celecoxib | Qualcox | Relif | Rigorixa;
  • (SE) Sweden: Celebra | Celebrex | Celecoxib ebb | Celecoxib Krka | Celecoxib medical valley | Celecoxib orion | Celecoxib sandoz | Celecoxib stada | Onsenal;
  • (SG) Singapore: Celebrex | Hovid celecoxib;
  • (SI) Slovenia: Celebrex;
  • (SK) Slovakia: Aclexa | Adaxib | Celebrex | Lectazib;
  • (TH) Thailand: Celebrex | Celxib | Cybec | Mediccoxib | Painex | Rancelex | Zobrex;
  • (TN) Tunisia: Adybrex | Algibrex | Celebrex | Celoxx | Coxibrex | Inflacox | Inibrex | Inicox 2 | X back;
  • (TR) Turkey: Celebrex | Celgyn;
  • (TW) Taiwan: Cecolex | Cecoxii | Celebrex | Celecolen | Celecor | Celexib | Celofen | Ecopain | Relecox | Selexib | Sincoxib;
  • (UA) Ukraine: Celebrex | Celecoxib norton | Denoxib | Lekoxa | Ranselex | Zycel;
  • (UG) Uganda: Unicelib | Zeecel | Zimcox | Zycel;
  • (UY) Uruguay: Ast-herix celecoxib | Celeb | Celebra | Celemax | Celexa | Celicox-2;
  • (VE) Venezuela, Bolivarian Republic of: Celebrex | Cexb | Coabib | Coxiben;
  • (VN) Viet Nam: Agilecox | Celosti | Ceozime | Coxirich | Doresyl | Ezelex | Foxicure | Gracox | Ikoxib | Locobile | Mibecerex | Paxicox | Sagacoxib | Vicoxib;
  • (ZA) South Africa: Aclexa | Anabrex | Celebrex | Celecoxib ascendis | Celecoxib unicorn | Coxep | Coxib | Coxleon | Cyretib | Lexib;
  • (ZW) Zimbabwe: Celofen | Colcibra | Unicelib
  1. Abraham NS, Hlatky MA, Antman EM, et al; ACCF/ACG/AHA. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. Circulation. 2010;122(24):2619-2633. doi:10.1161/CIR.0b013e318202f701 [PubMed 21060077]
  2. Abraham PA, Keane WF. Glomerular and interstitial disease induced by nonsteroidal anti-inflammatory drugs. Am J Nephrol. 1984;4(1):1-6. doi:10.1159/000166764 [PubMed 6731494]
  3. Ailani J, Burch RC, Robbins MS; Board of Directors of the American Headache Society. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. Headache. 2021;61(7):1021-1039. doi:10.1111/head.14153 [PubMed 34160823]
  4. Akhund L, Quinet RJ, Ishaq S. Celecoxib-related renal papillary necrosis. Arch Intern Med. 2003;163(1):114-115. doi:10.1001/archinte.163.1.114 [PubMed 12523925]
  5. Alonso JC, Ortega JD, Gonzalo MJ. Cutaneous reaction to oral celecoxib with positive patch test. Contact Dermatitis. 2004;50(1):48-49. doi:10.1111/j.0105-1873.2004.00271i.x [PubMed 15059110]
  6. Alper AB Jr, Meleg-Smith S, Krane NK. Nephrotic syndrome and interstitial nephritis associated with celecoxib. Am J Kidney Dis. 2002;40(5):1086-1090. doi:10.1053/ajkd.2002.36349 [PubMed 12407655]
  7. Alqahtani Z, Jamali F. Clinical outcomes of aspirin interaction with other non-steroidal anti-inflammatory drugs: a systematic review. J Pharm Pharm Sci. 2018;21(1s):29854. doi:10.18433/jpps29854 [PubMed 29891025]
  8. American College of Obstetricians and Gynecologists (ACOG). ACOG committee on clinical practice guidelines–obstetrics. Headaches in pregnancy and postpartum: ACOG clinical practice guideline no. 3. Obstet Gynecol. 2022;139(5):944-972. doi:10.1097/AOG.0000000000004766 [PubMed 35576364]
  9. American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins—Obstetrics. ACOG Practice Bulletin No. 209: Obstetric analgesia and anesthesia. Obstet Gynecol. 2019;133(3):e208-e225. doi:10.1097/AOG.0000000000003132 [PubMed 30801474]
  10. Ammar H, Ben Fredj N, Ben Fadhel N, et al. Celecoxib-induced bullous fixed drug eruption: an unusual presentation. Br J Clin Pharmacol. 2019;85(11):2638-2639. doi:10.1111/bcp.14072 [PubMed 31376180]
  11. Anderson PO, Sauberan JB. Modeling drug passage into human milk. Clin Pharmacol Ther. 2016;100(1):42-52. [PubMed 27060684]
  12. Anglin R, Yuan Y, Moayyedi P, Tse F, Armstrong D, Leontiadis GI. Risk of upper gastrointestinal bleeding with selective serotonin reuptake inhibitors with or without concurrent nonsteroidal anti-inflammatory use: a systematic review and meta-analysis. Am J Gastroenterol. 2014;109(6):811-819. doi:10.1038/ajg.2014.82 [PubMed 24777151]
  13. Atzori L, Pinna AL, Pau M, Aste N, Zucca M, Ferreli C. Adverse cutaneous reactions to selective cyclooxygenase 2 inhibitors: experience of an Italian drug-surveillance center. J Cutan Med Surg. 2006;10(1):31-35. doi:10.1007/7140.2006.00012 [PubMed 17241570]
  14. Baker M, Perazella MA. NSAIDs in CKD: are they safe? Am J Kidney Dis. 2020;76(4):546-557. doi:10.1053/j.ajkd.2020.03.023 [PubMed 32479922]
  15. Battistella M, Mamdami MM, Juurlink DN, Rabeneck L, Laupacis A. Risk of upper gastrointestinal hemorrhage in warfarin users treated with nonselective NSAIDs or COX-2 inhibitors. Arch Intern Med. 2005;165(2):189-192. doi:10.1001/archinte.165.2.189 [PubMed 15668365]
  16. Becker MA. Treatment of gout flares. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed June 14, 2020.
  17. Berger P, Dwyer D, Corallo CE. Toxic epidermal necrolysis after celecoxib therapy. Pharmacotherapy. 2002;22(9):1193-1195. doi:10.1592/phco.22.13.1193.33513 [PubMed 12222558]
  18. Bermas BL. Non-steroidal anti inflammatory drugs, glucocorticoids and disease modifying anti-rheumatic drugs for the management of rheumatoid arthritis before and during pregnancy. Curr Opin Rheumatol. 2014;26(3):334-340. [PubMed 24663106]
  19. Bhala N, Emberson J, Merhi A, et al; Coxib and traditional NSAID Trialists' (CNT) Collaboration. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382(9894):769-779. doi:10.1016/S0140-6736(13)60900-9 [PubMed 23726390]
  20. Bhangu A, Singh P, Fitzgerald JE, Slesser A, Tekkis P. Postoperative nonsteroidal anti-inflammatory drugs and risk of anastomotic leak: meta-analysis of clinical and experimental studies. World J Surg. 2014;38(9):2247-2257. doi:10.1007/s00268-014-2531-1 [PubMed 24682313]
  21. Bhatt DL, Scheiman J, Abraham NS, et al; American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2008;52(18):1502-1517. doi:10.1016/j.jacc.2008.08.002 [PubMed 19017521]
  22. Bhave G, Neilson EG. Volume depletion versus dehydration: how understanding the difference can guide therapy. Am J Kidney Dis. 2011;58(2):302-309. doi:10.1053/j.ajkd.2011.02.395 [PubMed 21705120]
  23. Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021;74(2):1014-1048. doi:10.1002/hep.31884 [PubMed 33942342]
  24. Bloor M, Paech M. Nonsteroidal anti-inflammatory drugs during pregnancy and the initiation of lactation. Anesth Analg. 2013;116(5):1063-1075. [PubMed 23558845]
  25. Blumberg M. Anaphylactic reaction to celecoxib with elevated serum tryptase and positive drug skin test. Ann Allergy Asthma Immunol. 2020;125(suppl):S54.
  26. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000;343(21):1520-1528. doi:10.1056/NEJM200011233432103 [PubMed 11087881]
  27. Brackett CC, Singh H, Block JH. Likelihood and mechanisms of cross-allergenicity between sulfonamide antibiotics and other drugs containing a sulfonamide functional group. Pharmacotherapy. 2004;24(7):856-870. [PubMed 15303450]
  28. Brix AE. Renal papillary necrosis. Toxicol Pathol. 2002;30(6):672-674. doi:10.1080/01926230290166760 [PubMed 12512867]
  29. Brockow K, Przybilla B, Aberer W, et al. Guideline for the diagnosis of drug hypersensitivity reactions: S2K-Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) and the German Dermatological Society (DDG) in collaboration with the Association of German Allergologists (AeDA), the German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Contact Dermatitis Research Group (DKG), the Swiss Society for Allergy and Immunology (SGAI), the Austrian Society for Allergology and Immunology (ÖGAI), the German Academy of Allergology and Environmental Medicine (DAAU), the German Center for Documentation of Severe Skin Reactions and the German Federal Institute for Drugs and Medical Products (BfArM). Allergo J Int. 2015;24(3):94-105. doi:10.1007/s40629-015-0052-6 [PubMed 26120552]
  30. Brophy PD. Changing the paradigm in pediatric acute kidney injury. J Pediatr. 2013;162(6):1094-1096. doi:10.1016/j.jpeds.2013.01.065 [PubMed 23453549]
  31. Burbach GJ, Vajkoczy P, Zuberbier T. Celecoxib desensitization: continued temozolomide/celecoxib chemotherapy after a celecoxib-induced hypersensitivity reaction. Anticancer Drugs. 2012;23(10):1118-1120. doi:10.1097/CAD.0b013e32835824fa [PubMed 23026982]
  32. Capone ML, Tacconelli S, Sciulli MG, et al. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. Circulation. 2004;109(12):1468-1471. doi:10.1161/01.CIR.0000124715.27937.78 [PubMed 15037526]
  33. Caughey GE, Cleland LG, Penglis PS, Gamble JR, James MJ. Roles of cyclooxygenase (COX)-1 and COX-2 in prostanoid production by human endothelial cells: selective up-regulation of prostacyclin synthesis by COX-2. J Immunol. 2001;167(5):2831-2838. doi:10.4049/jimmunol.167.5.2831 [PubMed 11509629]
  34. Celebrex (celecoxib) [prescribing information]. New York, NY: Pfizer Inc; April 2021.
  35. Celebrex (celecoxib) [prescribing information]. Morgantown, WV: Viatris Specialty LLC; February 2023.
  36. Celebrex (celecoxib) [product monograph]. Kirkland, Quebec, Canada: Upjohn Canada ULC; March 2022.
  37. Ch'ng A, Lowe M. Celecoxib allergies and cross-reactivity. Intern Med J. 2006;36(11):754-755. doi:10.1111/j.1445-5994.2006.01184.x [PubMed 17040369]
  38. Chamberlin KW, Silverman AR. Celecoxib-associated anaphylaxis. Ann Pharmacother. 2009;43(4):777-781. doi:10.1345/aph.1L593 [PubMed 19299321]
  39. Chamouard P, Walter P, Baumann R, Poupon R. Prolonged cholestasis associated with short-term use of celecoxib. Gastroenterol Clin Biol. 2005;29(12):1286-1288. doi:10.1016/s0399-8320(05)82223-7 [PubMed 16518289]
  40. Chan AL. Celecoxib-induced deep-vein thrombosis. Ann Pharmacother. 2005;39(6):1138. doi:10.1345/aph.1E603 [PubMed 15840730]
  41. Chan AT, Manson JE, Albert CM, et al. Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events. Circulation. 2006;113(12):1578-1587. doi:10.1161/CIRCULATIONAHA.105.595793 [PubMed 16534006]
  42. Chan CW, Yap YN. Pharmacotherapeutic management of gout in patients with cardiac disease [published online October 20, 2018]. Expert Opin Pharmacother. doi:10.1080/14656566.2018.1536747 [PubMed 30345832]
  43. Chan FK, Lanas A, Scheiman J, Berger MF, Nguyen H, Goldstein JL. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet. 2010;376(9736):173-179. doi:10.1016/S0140-6736(10)60673-3 [PubMed 20638563]
  44. Cheng Y, Austin SC, Rocca B, et al. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science. 2002;296(5567):539-541. doi:10.1126/science.1068711 [PubMed 11964481]
  45. Chou CI, Shih CJ, Chen YT, et al. Adverse effects of oral nonselective and cyclooxygenase-2-selective NSAIDs on hospitalization for acute kidney injury: a nested case-control cohort study. Medicine (Baltimore). 2016;95(9):e2645. doi:10.1097/MD.0000000000002645 [PubMed 26945352]
  46. Chou R, Gordon DB, de Leon-Casasola OA, et al. Management of postoperative pain: a clinical practice guideline from the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists' Committee on Regional Anesthesia, Executive Committee, and Administrative Council. J Pain. 2016;17(2):131-157. doi:10.1016/j.jpain.2015.12.008 [PubMed 26827847]
  47. Cimbollek S, Quiralte J, Avila R. COX-2 inhibitors in patients with sensitivity to nonselective NSAIDs. N Engl J Med. 2009;361(22):2197-2198. doi:10.1056/NEJMc0907208 [PubMed 19940308]
  48. Clive DM, Stoff JS. Renal syndromes associated with nonsteroidal antiinflammatory drugs. N Engl J Med. 1984;310(9):563-572. doi:10.1056/NEJM198403013100905 [PubMed 6363936]
  49. Cryer B, Feldman M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med. 1998;104(5):413-421. doi:10.1016/s0002-9343(98)00091-6 [PubMed 9626023]
  50. Daniels S, Robbins J, West CR, Nemeth MA. Celecoxib in the treatment of primary dysmenorrhea: results from two randomized, double-blind, active- and placebo-controlled, crossover studies. Clin Ther. 2009;31(6):1192-1208. doi:10.1016/j.clinthera.2009.06.003 [PubMed 19695387]
  51. Dathe K, Hultzsch S, Pritchard LW, Schaefer C. Risk estimation of fetal adverse effects after short-term second trimester exposure to non-steroidal anti-inflammatory drugs: a literature review. Eur J Clin Pharmacol. 2019;75(10):1347-1353. doi:10.1007/s00228-019-02712-2 [PubMed 31273431]
  52. Davies NM, McLachlan AJ, Day RO, Williams KM. Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet. 2000;38(3):225-242. doi:10.2165/00003088-200038030-00003 [PubMed 10749518]
  53. Delzer LM, Golightly LK, Kiser TH, Biggins SW, Lewis VJ, Kim II. Calcineurin inhibitor and nonsteroidal anti-inflammatory drug interaction: implications of changes in renal function associated with concurrent use. J Clin Pharmacol. 2018;58(11):1443-1451. doi:10.1002/jcph.1264 [PubMed 29799625]
  54. Doyle G, Jayawardena S, Ashraf E, et al. Efficacy and Tolerability of Nonprescription Ibuprofen Versus Celecoxib for Dental Pain. J Clin Pharmacol. 2002;42(8):912-919. [PubMed 12162474]
  55. Drago F, Brusati C, Desirello G, Cacciapuoti M, Rebora A. Cutaneous vasculitis induced by cyclo-oxygenase-2 selective inhibitors. J Am Acad Dermatol. 2004;51(6):1029-1030. doi:10.1016/j.jaad.2004.08.008 [PubMed 15583611]
  56. El Hajj II, Malik SM, Alwakeel HR, Shaikh OS, Sasatomi E, Kandil HM. Celecoxib-induced cholestatic liver failure requiring orthotopic liver transplantation. World J Gastroenterol. 2009;15(31):3937-3939. doi:10.3748/wjg.15.3937 [PubMed 19701976]
  57. Elyxyb (celecoxib) [prescribing information]. Raleigh, NC: Biodelivery Sciences International Inc; September 2021.
  58. Emery P, Zeidler H, Kvien TK, et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet. 1999;354(9196):2106-2111. doi:10.1016/S0140-6736(99)02332-6 [PubMed 10609815]
  59. Ernst EJ, Egge JA. Celecoxib-induced erythema multiforme with glyburide cross-reactivity. Pharmacotherapy. 2002;22(5):637-640. doi:10.1592/phco.22.8.637.33200 [PubMed 12013363]
  60. Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.
  61. FDA drug safety communication: FDA strengthens warning that non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) can cause heart attacks or strokes. Food and Drug Administration. Updated July 9, 2015. Accessed April 29, 2022. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-strengthens-warning-non-aspirin-nonsteroidal-anti-inflammatory
  62. Figueroa J, Ortega N, Almeida L, Blanco C, Castillo R. Sulfonamide allergy without cross-reactivity to celecoxib. Allergy. 2007;62(1):93. doi:10.1111/j.1398-9995.2006.01270.x [PubMed 17156357]
  63. Fisher AA, Le Couteur DG. Intracerebral hemorrhage following possible interaction between celecoxib and clopidogrel. Ann Pharmacother. 2001;35(12):1567-1569. doi:10.1345/aph.1A110 [PubMed 11793622]
  64. Friedman B, Orlet HK, Still JM, Law E. Toxic epidermal necrolysis due to administration of celecoxib (Celebrex). South Med J. 2002;95(10):1213-1214. [PubMed 12425513]
  65. Gaffo AL. Treatment of gout flares. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed October 9, 2023.
  66. Gagnon R, Julien M, Gold P. Selective celecoxib-associated anaphylactoid reaction. J Allergy Clin Immunol. 2003;111(6):1404-1405. doi:10.1067/mai.2003.1465 [PubMed 12789245]
  67. Gardiner SJ, Doogue MP, Zhang M, et al. Quantification of Infant Exposure to Celecoxib Through Breast Milk. Br J Clin Pharmacol. 2006;61(1):101-104. [PubMed 16390357]
  68. Garratty G, Arndt PA. Drugs that have been shown to cause drug-induced immune hemolytic anemia or positive direct antiglobulin tests: some interesting findings since 2007. Immunohematology. 2014;30(2):66-79. [PubMed 25247621]
  69. Geis GS, et al. Efficacy and Safety of Celecoxib, A Specific COX-2 Inhibitor, in Patients With Rheumatoid Arthritis. Arthritis Rheum. 1998;41(9)(suppl):316:1699.
  70. Gislason GH, Rasmussen JN, Abildstrom SZ, et al. Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure. Arch Intern Med. 2009;169(2):141-149. doi:10.1001/archinternmed.2008.525 [PubMed 19171810]
  71. Gladding PA, Webster MW, Farrell HB, Zeng IS, Park R, Ruijne N. The antiplatelet effect of six non-steroidal anti-inflammatory drugs and their pharmacodynamic interaction with aspirin in healthy volunteers. Am J Cardiol. 2008;101(7):1060-1063. doi:10.1016/j.amjcard.2007.11.054 [PubMed 18359332]
  72. Goeschke B, Braathen LR. Acute generalized exanthematic pustulosis: a case and an overview of side effects affecting the skin caused by celecoxib and other COX-2 inhibitors reported so far. Dermatology. 2004;209(1):53-56. doi:10.1159/000078588 [PubMed 15237269]
  73. Gómez de la Fuente E, Pampín Franco A, Caro Gutiérrez D, López Estebaranz JL. Fixed drug eruption due to etoricoxib in a patient with tolerance to celecoxib: the value of patch testing. Actas Dermosifiliogr. 2014;105(3):314-315. doi:10.1016/j.adengl.2013.04.022 [PubMed 24661957]
  74. Gooch K, Culleton BF, Manns BJ, et al. NSAID use and progression of chronic kidney disease. Am J Med. 2007;120(3):280.e1-280.e2807. doi:10.1016/j.amjmed.2006.02.015 [PubMed 17349452]
  75. Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet. 2005;365(9458):475-481. doi:10.1016/S0140-6736(05)17864-7 [PubMed 15705456]
  76. Grob M, Scheidegger P, Wüthrich B. Allergic skin reaction to celecoxib. Dermatology. 2000;201(4):383. doi:10.1159/000051569 [PubMed 11146365]
  77. Haag MD, Bos MJ, Hofman A, Koudstaal PJ, Breteler MM, Stricker BH. Cyclooxygenase selectivity of nonsteroidal anti-inflammatory drugs and risk of stroke. Arch Intern Med. 2008;168(11):1219-1224. doi:10.1001/archinte.168.11.1219 [PubMed 18541831]
  78. Hale TW, McDonald R, Boger J. Transfer of Celecoxib Into Human Milk. J Hum Lact. 2004;20(4):397-403. [PubMed 15479658]
  79. Handler J. Drug-induced hypertension. J Clin Hypertens (Greenwich). 2003;5(1):83-85. doi:10.1111/j.1524-6175.2003.01923.x [PubMed 12556663]
  80. Henao J, Hisamuddin I, Nzerue CM, Vasandani G, Hewan-Lowe K. Celecoxib-induced acute interstitial nephritis. Am J Kidney Dis. 2002;39(6):1313-1317. doi:10.1053/ajkd.2002.33412 [PubMed 12046048]
  81. Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ. 2005;330(7504):1366. doi:10.1136/bmj.330.7504.1366 [PubMed 15947398]
  82. Hong Y, Gengo FM, Rainka MM, Bates VE, Mager DE. Population pharmacodynamic modelling of aspirin- and Ibuprofen-induced inhibition of platelet aggregation in healthy subjects. Clin Pharmacokinet. 2008;47(2):129-137. doi:10.2165/00003088-200847020-00006 [PubMed 18193919]
  83. Horsley RD, Vogels ED, McField DAP, et al. Multimodal postoperative pain control is effective and reduces opioid use after laparoscopic Roux-en-Y gastric bypass. Obes Surg. 2019;29(2):394-400. doi:10.1007/s11695-018-3526-z [PubMed 30317488]
  84. Huerta C, Castellsague J, Varas-Lorenzo C, García Rodríguez LA. Nonsteroidal anti-inflammatory drugs and risk of ARF in the general population. Am J Kidney Dis. 2005;45(3):531-539. doi:10.1053/j.ajkd.2004.12.005 [PubMed 15754275]
  85. Ito S. Drug therapy for breast-feeding women. N Engl J Med. 2000;343(2):118-126. [PubMed 10891521]
  86. Johnson KK, Green DL, Rife JP, Limon L. Sulfonamide cross-reactivity: fact or fiction? [published correction appears in Ann Pharmacother. 2005;39(7-8):1373]. Ann Pharmacother. 2005;39(2):290-301. [PubMed 15644481]
  87. Kaewput W, Disorn P, Satirapoj B. Selective cyclooxygenase-2 inhibitor use and progression of renal function in patients with chronic kidney disease: a single-center retrospective cohort study. Int J Nephrol Renovasc Dis. 2016;9:273-278. doi:10.2147/IJNRD.S121698 [PubMed 27853386]
  88. Karim A, et al. Celecoxib, a Specific COX-2 Inhibitor, Lacks Significant Drug-Drug Interactions With Methotrexate or Warfarin. Arthritis Rheum. 1998;41(9)(suppl):315:1698. [PubMed 9485090]
  89. Kean WF, Lock CJ, Rischke J, Butt R, Buchanan WW, Howard-Lock H. Effect of R and S enantiomers of naproxen on aggregation and thromboxane production in human platelets. J Pharm Sci. 1989;78(4):324-327. doi:10.1002/jps.2600780413 [PubMed 2724096]
  90. Khan DA, Knowles SR, Shear NH. Sulfonamide hypersensitivity: fact and fiction. J Allergy Clin Immunol Pract. 2019;7(7):2116-2123. doi:10.1016/j.jaip.2019.05.034 [PubMed 31495421]
  91. Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl (2013). 2013;3(1):1-150. https://kdigo.org/wp-content/uploads/2017/02/KDIGO_2012_CKD_GL.pdf.
  92. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guidelines for the evaluation and management of chronic kidney disease. Kidney Inter, Suppl. 2013;3:1-150.
  93. Kim YJ, Lim KH, Kim MY, et al. Cross-reactivity to acetaminophen and celecoxib according to the type of nonsteroidal anti-inflammatory drug hypersensitivity. Allergy Asthma Immunol Res. 2014;6(2):156-162. doi:10.4168/aair.2014.6.2.156 [PubMed 24587953]
  94. Knijff-Dutmer EA, Kalsbeek-Batenburg EM, Koerts J, van de Laar MA. Platelet function is inhibited by non-selective non-steroidal anti-inflammatory drugs but not by cyclo-oxygenase-2-selective inhibitors in patients with rheumatoid arthritis. Rheumatology (Oxford). 2002;41(4):458-461. doi:10.1093/rheumatology/41.4.458 [PubMed 11961179]
  95. Knoppert DC, Stempak D, Baruchel S, et al. Celecoxib in Human Milk: A Case Report. Pharmacotherapy. 2003;23(1):97-100. [PubMed 12523466]
  96. Knowles S, Shapiro L, Shear NH. Should celecoxib be contraindicated in patients who are allergic to sulfonamides? Revisiting the meaning of 'sulfa' allergy. Drug Saf. 2001;24(4):239-247. doi:10.2165/00002018-200124040-00001 [PubMed 11330653]
  97. Kohli P, Steg PG, Cannon CP, et al. NSAID use and association with cardiovascular outcomes in outpatients with stable atherothrombotic disease. Am J Med. 2014;127(1):53-60.e1. doi:10.1016/j.amjmed.2013.08.017 [PubMed 24280110]
  98. Koncicki HM, Unruh M, Schell JO. Pain management in CKD: a guide for nephrology providers. Am J Kidney Dis. 2017;69(3):451-460. doi:10.1053/j.ajkd.2016.08.039 [PubMed 27881247]
  99. Kowalski ML, Makowska JS, Blanca M, et al. Hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs) - classification, diagnosis and management: review of the EAACI/ENDA(#) and GA2LEN/HANNA*. Allergy. 2011;66(7):818-829. doi:10.1111/j.1398-9995.2011.02557.x [PubMed 21631520]
  100. Krishnaswami S, Hutmacher MM, Robbins JL, et al. Dosing celecoxib in pediatric patients with juvenile rheumatoid arthritis. J Clin Pharmacol. 2012;52(8):1134-1149. doi:10.1177/0091270011412184 [PubMed 21878579]
  101. Kurella M, Bennett WM, Chertow GM. Analgesia in patients with ESRD: a review of available evidence. Am J Kidney Dis. 2003;42(2):217-228. doi:10.1016/s0272-6386(03)00645-0 [PubMed 12900801]
  102. La Grenade L, Lee L, Weaver J, et al. Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors. Drug Saf. 2005;28(10):917-924. doi:10.2165/00002018-200528100-00008 [PubMed 16180941]
  103. Lago P, Bettiol T, Salvadori S, et al. Safety and efficacy of ibuprofen versus indomethacin in preterm infants treated for patent ductus arteriosus: a randomised controlled trial. Eur J Pediatr. 2002;161(4):202-207. doi:10.1007/s00431-002-0915-y [PubMed 12014386]
  104. Laine L, Curtis SP, Cryer B, Kaur A, Cannon CP. Risk factors for NSAID-associated upper GI clinical events in a long-term prospective study of 34 701 arthritis patients. Aliment Pharmacol Ther. 2010;32(10):1240-1248. doi:10.1111/j.1365-2036.2010.04465.x [PubMed 20955443]
  105. Lane NE. Pain Management in Osteoarthritis: The Role of COX-2 Inhibitors. J Rheumatol. 1997;24(suppl 49):20-24. [PubMed 9002006]
  106. Lapi F, Azoulay L, Yin H, Nessim SJ, Suissa S. Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case-control study. BMJ. 2013;346:e8525. doi:10.1136/bmj.e8525 [PubMed 23299844]
  107. Larrey E, Patouraux S, Spreux A, et al. Fatal cholestatic hepatitis after a single dose of celecoxib. Clin Res Hepatol Gastroenterol. 2019;43(5):e82-e85. doi:10.1016/j.clinre.2018.10.007 [PubMed 30449626]
  108. Lee CH, Wang JD, Chen PC. Increased risk of hospitalization for acute hepatitis in patients with previous exposure to NSAIDs. Pharmacoepidemiol Drug Saf. 2010;19(7):708-714. doi:10.1002/pds.1966 [PubMed 20582911]
  109. Lee JH, Park HK, Heo J, et al. Drug rash with eosinophilia and systemic symptoms (DRESS) syndrome induced by celecoxib and anti-tuberculosis drugs. J Korean Med Sci. 2008;23(3):521-525. doi:10.3346/jkms.2008.23.3.521 [PubMed 18583892]
  110. Lee SK, Lee DY, Kim DJ, Kim MS, Lee UH, Hahm JH. Acute generalized exanthematous pustulosis induced by celecoxib. J Cutan Pathol. 2016;43(1):80-81. doi:10.1111/cup.12604 [PubMed 26488335]
  111. Leese PT, Hubbard RC, Karim A, Isakson PC, Yu SS, Geis GS. Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: a randomized, controlled trial. J Clin Pharmacol. 2000;40(2):124-132. doi:10.1177/00912700022008766 [PubMed 10664917]
  112. Levy MB, Fink JN. Anaphylaxis to celecoxib. Ann Allergy Asthma Immunol. 2001;87(1):72-73. doi:10.1016/S1081-1206(10)62327-7 [PubMed 11476468]
  113. Li L, Laidlaw T. Cross-reactivity and tolerability of celecoxib in adult patients with NSAID hypersensitivity. J Allergy Clin Immunol Pract. 2019;7(8):2891-2893.e4. doi:10.1016/j.jaip.2019.04.042 [PubMed 31100553]
  114. Lipsky PE, Isakson PC. Outcome of Specific COX-2 Inhibition in Rheumatoid Arthritis. J Rheumatol. 1997;24(suppl 49):9-14. [PubMed 9002004]
  115. Lipton RB, Munjal S, Dodick DW, Tepper SJ, Serrano D, Iaconangelo C. Acute treatment of migraine with celecoxib oral solution: results of a randomized, placebo-controlled clinical trial. J Pain Res. 2021;14:549-560. doi:10.2147/JPR.S287571 [PubMed 33658842]
  116. Marjoribanks J, Ayeleke RO, Farquhar C, Proctor M. Nonsteroidal anti-inflammatory drugs for dysmenorrhoea. Cochrane Database Syst Rev. 2015;2015(7):CD001751. doi:10.1002/14651858.CD001751.pub3 [PubMed 26224322]
  117. Martin E, Vickers B, Landau R, Reece-Stremtan S. ABM clinical protocol #28, peripartum analgesia and anesthesia for the breastfeeding mother. Breastfeed Med. 2018;13(3):164-171. doi:10.1089/bfm.2018.29087.ejm [PubMed 29595994]
  118. Mechanick JI, Apovian C, Brethauer S, et al. Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures - 2019 update: cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, the Obesity Society, American Society for Metabolic & Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists. Surg Obes Relat Dis. 2020;16(2):175-247. doi:10.1016/j.soard.2019.10.025 [PubMed 31917200]
  119. Mengle-Gaw L, et al. A Study of the Platelet Effects of SC-58635, A Novel COX-2 Selective Inhibitor. Arthritis Rheum. 1998;41(9)(suppl):93-374.
  120. Mérida E, Praga M. NSAIDs and nephrotic syndrome. Clin J Am Soc Nephrol. 2019;14(9):1280-1282. doi:10.2215/CJN.08090719 [PubMed 31416889]
  121. Miroux-Catarino A, Silva L, Amaro C, Ferreira ML, Viana I. Bullous fixed drug eruption induced by etoricoxib, confirmed by patch testing, with tolerance to celecoxib. Contact Dermatitis. 2019;81(5):388-389. doi:10.1111/cod.13339 [PubMed 31215658]
  122. Misurac JM, Knoderer CA, Leiser JD, Nailescu C, Wilson AC, Andreoli SP. Nonsteroidal anti-inflammatory drugs are an important cause of acute kidney injury in children. J Pediatr. 2013;162(6):1153-1159.e1. doi:10.1016/j.jpeds.2012.11.069 [PubMed 23360563]
  123. Mohammed EP, Stevens JM. Recurrence of Arthrotec-associated nephrotic syndrome with re-challenge. Clin Nephrol. 2000;53(6):483-485. [PubMed 10879670]
  124. Moore PA, Hersh EV. Celecoxib and Rofecoxib. The Role of COX-2 Inhibitors in Dental Practice. J Am Dent Assoc. 2001;132(4):451-456. [PubMed 11315375]
  125. Morales DR, Lipworth BJ, Guthrie B, Jackson C, Donnan PT, Santiago VH. Safety risks for patients with aspirin-exacerbated respiratory disease after acute exposure to selective nonsteroidal anti-inflammatory drugs and COX-2 inhibitors: meta-analysis of controlled clinical trials. J Allergy Clin Immunol. 2014;134(1):40-45. doi:10.1016/j.jaci.2013.10.057 [PubMed 24388008]
  126. Mukthinuthalapati PK, Fontana RJ, Vuppalanchi R, Chalasani N, Ghabril M. Celecoxib-induced liver injury: analysis of published case reports and cases reported to the Food and Drug Administration. J Clin Gastroenterol. 2018;52(2):114-122. doi:10.1097/MCG.0000000000000888 [PubMed 28795997]
  127. Nachimuthu S, Volfinzon L, Gopal L. Acute hepatocellular and cholestatic injury in a patient taking celecoxib. Postgrad Med J. 2001;77(910):548-550. doi:10.1136/pmj.77.910.548 [PubMed 11470953]
  128. Nash DM, Markle-Reid M, Brimble KS, et al. Nonsteroidal anti-inflammatory drug use and risk of acute kidney injury and hyperkalemia in older adults: a population-based study. Nephrol Dial Transplant. 2019;34(7):1145-1154. doi:10.1093/ndt/gfz062 [PubMed 31264694]
  129. National Institute for Health and Care Excellence. Drug allergy: diagnosis and management. Published September 3, 2014. Accessed April 29, 2022. https://www.nice.org.uk/guidance/cg183
  130. Needleman P, Isakson PC. The Discovery and Function of COX-2. J Rheumatol. 1997;24(suppl 49):6-8. [PubMed 9002003]
  131. Nissen SE, Yeomans ND, Solomon DH, et al. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N Engl J Med. 2016;375(26):2519-2529. doi:10.1056/NEJMoa1611593 [PubMed 27959716]
  132. Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 Inhibitors Parecoxib and Valdecoxib After Cardiac Surgery. N Engl J Med. 2005;352(11):1081-1091. [PubMed 15713945]
  133. Oates JA, FitzGerald GA, Branch RA, Jackson EK, Knapp HR, Roberts LJ 2nd. Clinical implications of prostaglandin and thromboxane A2 formation (2). N Engl J Med. 1988;319(12):761-767. doi:10.1056/NEJM198809223191206 [PubMed 3045551]
  134. Ohlsson A, Walia R, Shah SS. Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database Syst Rev. 2013;(4):CD003481. doi:10.1002/14651858.CD003481.pub5 [PubMed 23633310]
  135. Otani K, Tanigawa T, Watanabe T, et al. Microbiota plays a key role in non-steroidal anti-inflammatory drug-induced small intestinal damage. Digestion. 2017;95(1):22-28. doi:10.1159/000452356 [PubMed 28052268]
  136. Pal A, Shenoy S, Gautam A, et al. Pharmacokinetics of DFN-15, a novel oral solution of celecoxib, versus celecoxib 400-mg capsules: a randomized crossover study in fasting healthy volunteers. Clin Drug Investig. 2017;37(10):937-946. doi:10.1007/s40261-017-0548-6 [PubMed 28748412]
  137. Papaioannides DH, Korantzopoulos PG, Giotis CH. Aseptic meningitis possibly associated with celecoxib. Ann Pharmacother. 2004;38(1):172. doi:10.1345/aph.1D238 [PubMed 14742817]
  138. Papatheodoridis GV, Sougioultzis S, Archimandritis AJ. Effects of Helicobacter pylori and nonsteroidal anti-inflammatory drugs on peptic ulcer disease: a systematic review. Clin Gastroenterol Hepatol. 2006;4(2):130-142. doi:10.1016/j.cgh.2005.10.006 [PubMed 16469671]
  139. Perna AG, Woodruff CA, Markus RF, Hsu S. Toxic epidermal necrolysis as a complication of treatment with celecoxib. Dermatol Online J. 2003;9(5):25. [PubMed 14996398]
  140. Piper JM, Ray WA, Daugherty JR, Griffin MR. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med. 1991;114(9):735-740. doi:10.7326/0003-4819-114-9-735 [PubMed 2012355]
  141. Portenoy RK, Ahmed E, Keilson YY. Cancer pain management: Use of acetaminophen and nonsteroidal anti-inflammatory drugs. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed June 29, 2022.
  142. Rahman S, Malcoun A. Nonsteroidal antiinflammatory drugs, cyclooxygenase-2, and the kidneys. Prim Care. 2014;41(4):803-821. doi:10.1016/j.pop.2014.09.001 [PubMed 25439535]
  143. Ray WA, Varas-Lorenzo C, Chung CP, et al. Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease. Circ Cardiovasc Qual Outcomes. 2009;2(3):155-163. doi:10.1161/CIRCOUTCOMES.108.805689 [PubMed 20031832]
  144. Reece-Stremtan S, Campos M, Kokajko L; Academy of Breastfeeding Medicine. ABM clinical protocol #15: analgesia and anesthesia for the breastfeeding mother, revised 2017. Breastfeed Med. 2017;12(9):500-506. doi:10.1089/bfm.2017.29054.srt [PubMed 29624435]
  145. Refer to manufacturer's labeling,
  146. Regis AC, Germann CA, Crowell JG. Myocardial infarction in the setting of anaphylaxis to celecoxib: a case of Kounis syndrome. J Emerg Med. 2015;49(2):e39-e43. doi:10.1016/j.jemermed.2015.02.044 [PubMed 25989969]
  147. Rostom A, Muir K, Dubé C, et al. Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane Collaboration systematic review. Clin Gastroenterol Hepatol. 2007;5(7):818-768. doi:10.1016/j.cgh.2007.03.011 [PubMed 17556027]
  148. Ruschitzka F, Borer JS, Krum H, et al. Differential blood pressure effects of ibuprofen, naproxen, and celecoxib in patients with arthritis: the PRECISION-ABPM (Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus Ibuprofen or Naproxen Ambulatory Blood Pressure Measurement) Trial. Eur Heart J. 2017;38(44):3282-3292. doi:10.1093/eurheartj/ehx508 [PubMed 29020251]
  149. Sammaritano LR, Bermas BL, Chakravarty EE, et al. 2020 American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. Arthritis Rheumatol. 2020;72(4):529‐556. doi:10.1002/art.41191 [PubMed 32090480]
  150. Sands G, Shell B, Zhang R. Adverse events in patients with blood loss: a pooled analysis of 51 clinical studies from the celecoxib clinical trial database. Open Rheumatol J. 2012;6:44-49. doi:10.2174/1874312901206010044 [PubMed 22629288]
  151. Schjerning O, Larsen TB, Damkier P. The impact of selective and non-selective non-steroid anti-inflammatory drugs on secondary hemostasis in healthy volunteers. Thromb Res. 2009;124(2):208-212. doi:10.1016/j.thromres.2009.01.017 [PubMed 19269020]
  152. Schjerning Olsen AM, Fosbøl EL, Gislason GH. The impact of NSAID treatment on cardiovascular risk - insight from Danish observational data. Basic Clin Pharmacol Toxicol. 2014;115(2):179-184. doi:10.1111/bcpt.12244 [PubMed 24690187]
  153. Schjerning Olsen AM, Fosbøl EL, Lindhardsen J, et al. Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. Circulation. 2011;123(20):2226-2235. doi:10.1161/CIRCULATIONAHA.110.004671 [PubMed 21555710]
  154. Schjerning Olsen AM, Gislason GH, McGettigan P, et al. Association of NSAID use with risk of bleeding and cardiovascular events in patients receiving antithrombotic therapy after myocardial infarction. JAMA. 2015;313(8):805-814. doi:10.1001/jama.2015.0809 [PubMed 25710657]
  155. Schmidt M, Lamberts M, Schjerning Olsen AM, et al. Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: review and position paper by the working group for Cardiovascular Pharmacotherapy of the European Society of Cardiology. Eur Heart J. 2016;37(13):1015-1023. doi:10.1093/eurheartj/ehv505 [PubMed 26984863]
  156. Schneider F, Meziani F, Chartier C, Alt M, Jaeger A. Fatal allergic vasculitis associated with celecoxib. Lancet. 2002;359(9309):852-853. doi:10.1016/S0140-6736(02)07922-9 [PubMed 11897288]
  157. Schneider V, Lévesque LE, Zhang B, Hutchinson T, Brophy JM. Association of selective and conventional nonsteroidal antiinflammatory drugs with acute renal failure: a population-based, nested case-control analysis. Am J Epidemiol. 2006;164(9):881-889. doi:10.1093/aje/kwj331 [PubMed 17005625]
  158. Schrijvers R, Gilissen L, Chiriac AM, Demoly P. Pathogenesis and diagnosis of delayed-type drug hypersensitivity reactions, from bedside to bench and back. Clin Transl Allergy. 2015;5:31. doi:10.1186/s13601-015-0073-8 [PubMed 26339470]
  159. Schumacher HR, Berger MF, Li-Yu J, Perez-Ruiz F, Burgos-Vargas R, Li C. Efficacy and tolerability of celecoxib in the treatment of acute gouty arthritis: a randomized controlled trial. J Rheumatol. 2012;39(9):1859-1866. doi:10.3899/jrheum.110916 [PubMed 22859357]
  160. Schuster C, Wüthrich B. Anaphylactic drug reaction to celecoxib and sulfamethoxazole: cross reactivity or coincidence? Allergy. 2003;58(10):1072. doi:10.1034/j.1398-9995.2003.00116.x [PubMed 14510732]
  161. Schwedt TJ, Garza I. Acute treatment of migraine in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed March 10, 2022.
  162. Shah GM, Muhalwas KK, Winer RL. Renal papillary necrosis due to ibuprofen. Arthritis Rheum. 1981;24(9):1208-1210. doi:10.1002/art.1780240917 [PubMed 7306246]
  163. Shapiro LE, Knowles SR, Weber E, Neuman MG, Shear NH. Safety of celecoxib in individuals allergic to sulfonamide: a pilot study. Drug Saf. 2003;26(3):187-195. doi:10.2165/00002018-200326030-00004 [PubMed 12580647]
  164. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000;284(10):1247-1255. doi:10.1001/jama.284.10.1247 [PubMed 10979111]
  165. Simon LS, et al. Preliminary Study of the Safety and Efficacy of SC-58635, a Novel Cyclo-oxygenase 2 Inhibitor: Efficacy and Safety in Two Placebo-Controlled Trials in Osteoarthritis and Rheumatoid Arthritis, and Studies of Gastrointestinal and Platelet Effects. Arthritis Rheum. 1998;41:1591-1602. [PubMed 9751091]
  166. Simon LS, Weaver AL, Graham DY, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA. 1999;282(20):1921-1928. doi:10.1001/jama.282.20.1921 [PubMed 10580457]
  167. Singh G, Fort JG, Goldstein JL, et al; SUCCESS-I investigators. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study. Am J Med. 2006;119(3):255-266. doi:10.1016/j.amjmed.2005.09.054 [PubMed 16490472]
  168. Sivera F, Andres M, Carmona L, et al. Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. Ann Rheum Dis. 2014;73(2):328-335. [PubMed 23868909]
  169. Slatore CG, Tilles SA. Sulfonamide hypersensitivity. Immunol Allergy Clin North Am. 2004;24(3):477-490. [PubMed 15242722]
  170. Solomon DH, Husni ME, Libby PA, et al. The risk of major NSAID toxicity with celecoxib, ibuprofen, or naproxen: a secondary analysis of the PRECISION trial. Am J Med. 2017;130(12):1415-1422.e4. doi:10.1016/j.amjmed.2017.06.028 [PubMed 28756267]
  171. Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular Risk Associated With Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention. N Engl J Med. 2005;352(11):1071-180. [PubMed 15713944]
  172. Soni P, Shell B, Cawkwell G, Li C, Ma H. The hepatic safety and tolerability of the cyclooxygenase-2 selective NSAID celecoxib: pooled analysis of 41 randomized controlled trials. Curr Med Res Opin. 2009;25(8):1841-1851. doi:10.1185/03007990903018279 [PubMed 19530981]
  173. Sriuttha P, Sirichanchuen B, Permsuwan U. Hepatotoxicity of nonsteroidal anti-inflammatory drugs: a systematic review of randomized controlled trials. Int J Hepatol. 2018;2018:5253623. doi:10.1155/2018/5253623 [PubMed 29568654]
  174. Stempak D, Bukaveckas BL, Linder M, et al. Cytochrome P450 2C9 Genotype: Impact on Celecoxib Safety and Pharmacokinetics in a Pediatric Patient. Clin Pharmacol Ther. 2005;78(3):309-310. [PubMed 16153401]
  175. Stempak D, Gammon J, Halton J, et al. Modulation of Celecoxib Pharmacokinetics by Food in Pediatric Patients. Clin Pharmacol Ther. 2005a;77(3):226-228. [PubMed 15735617]
  176. Stempak D, Gammon J, Klein J, et al. Single-Dose and Steady-State Pharmacokinetics of Celecoxib in Children. Clin Pharmacol Ther. 2002;72(5):490-497. [PubMed 12426512]
  177. "Sulfonamide Cross-reactivity." Med Lett Drugs Ther. 2019;61(1568):44-46. [PubMed 31022157]
  178. Szeto CC, Sugano K, Wang JG, et al. Non-steroidal anti-inflammatory drug (NSAID) therapy in patients with hypertension, cardiovascular, renal or gastrointestinal comorbidities: joint APAGE/APLAR/APSDE/APSH/APSN/PoA recommendations. Gut. 2020;69(4):617-629. doi:10.1136/gutjnl-2019-319300 [PubMed 31937550]
  179. Teerawattananon C, Tantayakom P, Suwanawiboon B, Katchamart W. Risk of perioperative bleeding related to highly selective cyclooxygenase-2 inhibitors: a systematic review and meta-analysis. Semin Arthritis Rheum. 2017;46(4):520-528. doi:10.1016/j.semarthrit.2016.07.008 [PubMed 27569276]
  180. Theken KN, Lee CR, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium guideline (CPIC) for CYP2C9 and nonsteroidal anti-inflammatory drugs. Clin Pharmacol Ther. 2020;108(2):191-200. doi:10.1002/cpt.1830 [PubMed 32189324]
  181. Thorell A, MacCormick AD, Awad S, et al. Guidelines for perioperative care in bariatric surgery: Enhanced Recovery After Surgery (ERAS) Society recommendations. World J Surg. 2016;40(9):2065-2083. doi:10.1007/s00268-016-3492-3 [PubMed 26943657]
  182. Tornero P, De Barrio M, Baeza ML, Herrero T. Cross-reactivity among p-amino group compounds in sulfonamide fixed drug eruption: diagnostic value of patch testing. Contact Dermatitis. 2004;51(2):57-62. doi:10.1111/j.0105-1873.2004.00274.x [PubMed 15373844]
  183. Trelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ. 2011;342:c7086. doi:10.1136/bmj.c7086 [PubMed 21224324]
  184. US Food and Drug Administration (FDA). FDA Drug Safety Communication: FDA strengthens warning that non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) can cause heart attacks or strokes. 2015. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-strengthens-warning-non-aspirin-nonsteroidal-anti-inflammatory.
  185. US Food and Drug Administration (FDA). FDA recommends avoiding use of NSAIDs in pregnancy at 20 weeks or later because they can result in low amniotic fluid. https://www.fda.gov/drugs/drug-safety-and-availability/fda-recommends-avoiding-use-nsaids-pregnancy-20-weeks-or-later-because-they-can-result-low-amniotic. Published October 15, 2020. Accessed October 20, 2020.
  186. Vadivel N, Trikudanathan S, Singh AK. Analgesic nephropathy. Kidney Int. 2007;72(4):517-520. doi:10.1038/sj.ki.5002251 [PubMed 17410098]
  187. Villanueva M, Heckenberger R, Palmér M, Schrör K. Stereospecific and non-stereospecific effects of ibuprofen on human platelet and polymorphonuclear leukocyte functions. Agents Actions Suppl. 1992;37:162-170. doi:10.1007/978-3-0348-7262-1_22 [PubMed 1321554]
  188. Viola M, Quaratino D, Gaeta F, et al. Celecoxib tolerability in patients with hypersensitivity (mainly cutaneous reactions) to nonsteroidal anti-inflammatory drugs. Int Arch Allergy Immunol. 2005;137(2):145-150. doi:10.1159/000085794 [PubMed 15897671]
  189. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci U S A. 1999;96(13):7563-7568. doi:10.1073/pnas.96.13.7563 [PubMed 10377455]
  190. Watson DJ, Rhodes T, Cai B, Guess HA. Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. Arch Intern Med. 2002;162(10):1105-1110. doi:10.1001/archinte.162.10.1105 [PubMed 12020179]
  191. Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med. 1999;106(5B):13S-24S. doi:10.1016/s0002-9343(99)00113-8 [PubMed 10390124]
  192. White AA, Stevenson DD. Aspirin-exacerbated respiratory disease. N Engl J Med. 2018;379(11):1060-1070. doi:10.1056/NEJMra1712125 [PubMed 30207919]
  193. Wyplosz B, Vautier S, Lillo-Le Louët A, Capron L. Tolerance of diclofenac after hypersensitivity to celecoxib and to nabumetone. Br J Clin Pharmacol. 2006;61(4):474. doi:10.1111/j.1365-2125.2005.02576.x [PubMed 16542210]
  194. Yancy CW, Jessup M, Bozkurt B, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128(16):e240-e327. [PubMed 23741058]
  195. Yancy CW, Jessup M, Bozkurt B, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62(16):e147-e239. doi:10.1016/j.jacc.2013.05.019 [PubMed 23747642]
  196. Yeomans ND, Graham DY, Husni ME, et al. Randomised clinical trial: gastrointestinal events in arthritis patients treated with celecoxib, ibuprofen or naproxen in the PRECISION trial. Aliment Pharmacol Ther. 2018;47(11):1453-1463. doi:10.1111/apt.14610 [PubMed 29667211]
  197. Zhan M, Doerfler RM, Xie D, et al. Association of opioids and nonsteroidal anti-inflammatory drugs with outcomes in CKD: findings from the CRIC (Chronic Renal Insufficiency Cohort) study. Am J Kidney Dis. 2020;76(2):184-193. doi:10.1053/j.ajkd.2019.12.010 [PubMed 32317121]
  198. Zhang W, Doherty M, Bardin T, et al; EULAR Standing Committee for International Clinical Studies Including Therapeutics. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006;65(10):1312-1324. [PubMed 16707532]
  199. Zipser RD, Hoefs JC, Speckart PF, Zia PK, Horton R. Prostaglandins: modulators of renal function and pressor resistance in chronic liver disease. J Clin Endocrinol Metab. 1979;48(6):895-900. doi:10.1210/jcem-48-6-895 [PubMed 447795]
Topic 8847 Version 702.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟